View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Aug. 03, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Chemours Co
Entity Central Index Key	0001627223
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		181,545,136

Interim Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Millions

3 Months Ended

6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Jun. 30, 2016

Jun. 30, 2015

Income Statement [Abstract]

Net sales

$ 1,383

$ 1,508

$ 2,680

$ 2,871

Cost of goods sold

1,116

1,282

2,212

2,393

Gross profit

267

226

468

478

Selling, general and administrative expense

174

157

307

324

Research and development expense

Employee separation and asset related charges, net

Total expenses

258

245

432

435

Equity in earnings of affiliates

Interest expense, net

(50)

(28)

(106)

(28)

Other (expense) income, net

(4)

(Loss) income before income taxes

(41)

(18)

(Benefit from) provision for income taxes

(23)

(5)

Net (loss) income

(18)

Less: Net income attributable to noncontrolling interests

Net (loss) income attributable to Chemours

$ (18)

$ 33

$ 25

Per share data

Basic (loss) earnings per share of common stock (USD per share)

^[1]

$ (0.10)

$ 0.18

$ 0.14

Diluted (loss) earnings per share of common stock (USD per share)

^[1]

(0.10)

0.18

0.14

Dividends per share of common stock (USD per share)

^[1]

$ 0.03

$ 0.55

$ 0.06

$ 0.55

[1]

On July 1, 2015, E. I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours' common stock to holders of its common stock. Basic and diluted earnings per common share and dividends per common share for the three and six months ended June 30, 2015 were calculated using the number of shares distributed on July 1, 2015. Refer to Note 9 for information regarding the calculation of basic and diluted earnings per share.

Interim Consolidated Statements of Operations (Unaudited) (Parenthetical)	Jul. 01, 2015 shares
Income Statement [Abstract]
Stock issued, common stock	180,966,833

Interim Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Millions

3 Months Ended

6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Jun. 30, 2016

Jun. 30, 2015

Statement of Comprehensive Income [Abstract]

Net (loss) Income, pre-tax

$ (41)

$ (18)

$ 28

$ 40

Net (loss) Income, tax

(15)

Net (loss) income

(18)

Other comprehensive income (loss):

Unrealized gain (loss) on net investment hedge, pre-tax

(3)

Unrealized gain (loss) on net investment hedge, tax

Unrealized gain (loss) on net investment hedge, after-tax

(3)

Cumulative translation adjustments, pre-tax

(9)

(28)

(234)

Cumulative translation adjustment, tax

Cumulative translation adjustment, after-tax

(9)

(28)

(234)

Pension benefit plans, net:

Net gain (loss), pre-tax

(7)

Net gain (loss), tax

(1)

Net gain (loss), after-tax

(6)

Effect of foreign exchange rates, pre-tax

(9)

(1)

Effect of foreign exchange rates, tax

(6)

Effect of foreign exchange rates, after-tax

(7)

Reclassifications to net income (loss):

Amortization of prior service cost, pre-tax

^[1]

(1)

Amortization of prior service cost, tax

^[1]

Amortization of prior service cost, after tax

^[1]

(1)

Amortization of loss, pre-tax

^[1]

Amortization of loss, tax

^[1]

(2)

(3)

(1)

Amortization of loss, after tax

^[1]

Curtailment gain, pre-tax

^[1]

(2)

Curtailment gain, tax

^[1]

Curtailment gain, after-tax

^[1]

(2)

(1)

Pension benefit plans, net, pre-tax

^[1]

(5)

Pension benefit plans, net, tax

^[1]

(1)

(8)

Pension benefit plans, net, after-tax

^[1]

(3)

Other comprehensive loss, pre-tax

(3)

(33)

(199)

Other comprehensive income (loss), tax

(1)

(8)

Other comprehensive income (loss), after-tax

(4)

(31)

(207)

Comprehensive (loss) income, pre-tax

(44)

(51)

(159)

Comprehensive income (loss), tax

(23)

Comprehensive income (loss), after-tax

(22)

(49)

(182)

Comprehensive income (loss) attributable to noncontrolling Interests, pre-tax

Comprehensive income (loss) attributable to noncontrolling interest, tax

Comprehensive income (loss) attributable to noncontrolling interest, after-tax

Comprehensive (loss) income attributable to Chemours, pre-tax

(44)

(51)

(159)

Comprehensive (loss) income attributable to Chemours, tax

(23)

Comprehensive (loss) income attributable to Chemours, after-tax

$ (22)

$ (49)

$ 40

$ (182)

[1]	These other comprehensive income (loss) components are included in the computation of net periodic benefit costs (refer to Note 18 for further information).

Interim Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash	$ 383	$ 366
Accounts and notes receivable - trade, net	939	859
Inventories	892	972
Prepaid expenses and other	52	58
Assets held-for-sale	26	46
Total current assets	2,292	2,301
Property, plant and equipment	8,334	9,015
Less: Accumulated depreciation	(5,444)	(5,838)
Net property, plant and equipment	2,890	3,177
Goodwill	153	166
Other intangible assets, net	8	10
Investments in affiliates	157	136
Assets held-for-sale	352	0
Other assets	369	508
Total assets	6,221	6,298
Current liabilities:
Accounts payable	875	973
Short-term borrowings and current maturities of long-term debt	36	39
Other accrued liabilities	533	454
Total current liabilities	1,444	1,466
Long-term debt, net	3,823	3,915
Deferred income taxes	202	234
Other liabilities	583	553
Total liabilities	6,052	6,168
Commitments and contingent liabilities
Equity
Common stock (par value $.01 per share; 810,000,000 shares authorized; 181,491,426 shares issued and outstanding as of June 30, 2016)	2	2
Additional paid-in capital	774	775
Accumulated deficit	(82)	(115)
Accumulated other comprehensive loss	(529)	(536)
Total Chemours stockholders' equity	165	126
Noncontrolling interests	4	4
Total equity	169	130
Total liabilities and equity	$ 6,221	$ 6,298

Interim Consolidated Balance Sheet (Parenthetical)	Jun. 30, 2016 $ / shares shares
Statement of Financial Position [Abstract]
Common stock , par value (USD per share) \| $ / shares	$ 0.01
Common stock, shares authorized	810,000,000
Common stock, shares issued	181,491,426
Common stock, shares outstanding	181,491,426

Interim Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Millions	Total	Common Stock [Member]	DuPont Company Net Investment [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Noncontrolling Interests [Member]
Shares, beginning balance at Dec. 31, 2014		0
Total stockholders' equity, beginning balance at Dec. 31, 2014	$ 3,673	$ 0	$ 3,650	$ 0	$ 19	$ 0	$ 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	25		25
Establishment of pension plans, net and related accumulated other comprehensive income (loss)	110		357		(247)
Dividends	(100)		(100)
Other comprehensive income (loss)	(207)				(207)
Non-cash debt exchange	(507)		(507)
Cash provided at separation by DuPont	247		247
Net transfers to DuPont	(2,836)		(2,836)
Shares, ending balance at Jun. 30, 2015		0
Total stockholders' equity, ending balance at Jun. 30, 2015	405	$ 0	836	0	(435)	0	4
Shares, beginning balance at Dec. 31, 2015		181,069,751
Total stockholders' equity, beginning balance at Dec. 31, 2015	130	$ 2	0	775	(536)	(115)	4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	33					33
Common stock issued - compensation plans (in shares)		421,675
Dividends	(11)			(11)
Other comprehensive income (loss)	7				7
Stock based compensation	10			10
Shares, ending balance at Jun. 30, 2016		181,491,426
Total stockholders' equity, ending balance at Jun. 30, 2016	$ 169	$ 2	$ 0	$ 774	$ (529)	$ (82)	$ 4

Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating activities
Net income	$ 33	$ 25
Adjustments to reconcile net income to cash provided by (used for) operating activities:
Depreciation and amortization	139	131
Amortization of debt issuance costs and discount	11	2
Gain on sale of assets and business	(88)	0
Equity in earnings of affiliates	(9)	(11)
Deferred tax benefits	(36)	(31)
Asset related charges	63	0
Other operating charges, net	14	2
Accounts and notes receivable - trade, net	(92)	(205)
Inventories and other operating assets	85	(68)
Accounts payable and other operating liabilities	6	(78)
Cash provided by (used for) operating activities	126	(233)
Investing activities
Purchases of property, plant and equipment	(168)	(287)
Proceeds from sales of assets and business	150	8
Foreign exchange contract settlements	0	(12)
Investment in affiliates	0	(32)
Cash used for investing activities	(18)	(323)
Financing activities
Proceeds from issuance of debt, net	0	3,490
Debt repayments	(95)	0
Deferred financing fees	(2)	(77)
Dividends paid	(11)	0
Cash provided at separation by DuPont	0	247
Net transfers to DuPont	0	(2,857)
Cash (used for) provided by financing activities	(108)	803
Effect of exchange rate changes on cash	17	0
Increase in cash	17	247
Cash at beginning of period	366	0
Cash at end of period	383	247
Non-cash investing activities:
Change in property, plant and equipment included in accounts payable	$ 10	$ (35)

Background and Description of the Business	6 Months Ended
Background and Description of the Business	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Description of the Business	Background and Description of the Business The Chemours Company (Chemours or the Company) delivers customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial, mining and oil refining. Principal products include titanium dioxide (TiO₂), refrigerants, industrial fluoropolymer resins, sodium cyanide and sulfuric acid. Chemours consists of three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. Chemours is globally operated with manufacturing facilities, sales centers, administrative offices and warehouses located throughout the world. Chemours' operations are primarily located in the United States (U.S.), Canada, Mexico, Brazil, the Netherlands, Belgium, China, Taiwan, Japan, Switzerland, Singapore, Hong Kong, India, the United Kingdom and France. As of June 30, 2016, Chemours consists of 34 production facilities globally, five dedicated to Titanium Technologies, 16 dedicated to Fluoroproducts, 12 dedicated to Chemical Solutions (which includes nine production facilities of the Clean & Disinfect and Sulfur businesses classified as held-for-sale, see Note 6) and one that supports the Fluoroproducts and Chemical Solutions segments. Effective prior to the opening of trading on the New York Stock Exchange (NYSE) on July 1, 2015 (the Distribution Date), E. I. du Pont de Nemours and Company (DuPont) completed the previously announced separation of the businesses comprising DuPont’s Performance Chemicals reporting segment, and certain other assets and liabilities, into Chemours, a separate and distinct public company. The separation was completed by way of a distribution of all of the then-outstanding shares of common stock of Chemours through a dividend in kind of Chemours’ common stock (par value $0.01) to holders of DuPont common stock (par value $0.30) as of the close of business on June 23, 2015 (the Record Date) (the transaction referred to herein as the Distribution). On the Distribution Date, each holder of DuPont's common stock received one share of Chemours' common stock for every five shares of DuPont's common stock held on the Record Date. The separation was completed pursuant to a Separation Agreement and other agreements with DuPont related to the separation, including an Employee Matters Agreement, a Tax Matters Agreement, a Transition Services Agreement and an Intellectual Property Cross-License Agreement. These agreements govern the relationship between Chemours and DuPont following the separation and provided for the allocation of various assets, liabilities, rights and obligations. These agreements also include arrangements for transition services to be provided by DuPont to Chemours. Unless the context otherwise requires, references in these Notes to the Consolidated Financial Statements to “we,” “us,” “our,” “Chemours” and the “Company” refer to The Chemours Company and its consolidated subsidiaries after giving effect to the Distribution.

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) for interim financial information. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year and the year-end consolidated balance sheet does not include all disclosures required by accounting principles generally accepted in the United States of America. As such, these interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015. Unless otherwise stated, references to years and three and six month periods relate to Chemours' fiscal years and three and six month periods. Certain reclassifications of prior year's data have been made to conform to current period presentation. Chemours did not operate as a separate, stand-alone entity for the full period covered by the 2015 interim consolidated financial statements. Prior to our separation on July 1, 2015, Chemours operations were included in DuPont's financial results in different legal forms, including but not limited to wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses and a majority owned joint venture. For periods prior to July 1, 2015, the interim consolidated financial statements have been prepared from DuPont’s historical accounting records and are presented on a stand-alone basis as if the business operations had been conducted independently from DuPont. DuPont and its subsidiaries’ net investments in these operations are shown in lieu of Stockholder’s Equity in the interim consolidated financial statements for the period ended June 30, 2015. The interim consolidated financial statements for the period ended June 30, 2015 include the historical operations, assets and liabilities of the legal entities that were considered to comprise the Chemours business, including certain environmental remediation and litigation obligations for which Chemours has indemnified DuPont. All of the allocations and estimates in the interim consolidated financial statements prior to July 1, 2015 were based on assumptions that management believes are reasonable. However, the interim consolidated financial statements for the three and six months ended June 30, 2015 included herein may not be indicative of the results of operations and cash flows of Chemours in the future or if Chemours had been a separate, stand-alone entity during those periods. The net transfers from DuPont in the Interim Consolidated Statements of Stockholders’ Equity for the six months ended June 30, 2015 include a non-cash contribution from DuPont of $93. This non-cash contribution occurred during physical separation activities at shared production facilities in the United States prior to the separation.

Recent Accounting Pronouncements	6 Months Ended
Recent Accounting Pronouncements	Jun. 30, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March through May 2016, the Financial Accounting Standards Board (FASB) issued various updates to the Accounting Standards Update (ASU) No. 2014-09, “Revenue from contracts with customers (Topic 606).” The additional updates provide further clarifications on certain objectives and application of the core principle of Topic 606 for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The guidance is effective for public entities for annual and interim periods beginning after December 15, 2016 (original effective date), with one year deferral permitted from the original effective date. Chemours is currently evaluating the impact of adopting the guidance on its financial positions and results of operations and expects to adopt the guidance effective January 1, 2018. In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718).” The update sets forth areas for simplification within several aspects of the accounting for shared-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this update are effective for fiscal periods, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted for any entity in any interim or annual period. Chemours is currently evaluating the impact of adopting this guidance but does not expect the adoption will have a significant impact on its financial position or results of operations. Also, in March 2016, the FASB issued ASU 2016-07, “Investments—Equity Method and Joint Ventures (Topic 323).” The amendments eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments should be applied prospectively upon their effective date to increases in the level of ownership interest or degree of influence that result in the adoption of the equity method. Earlier application is permitted. Adoption of this guidance is not expected to have a significant impact on the Company's financial position or results of operations. Further, in March 2016, the FASB issued ASU 2016-06, “Derivatives and Hedging (Topic 815), Contingent Put and Call Options in Debt Instruments,” which clarifies Topic 815 requirements for assessing whether contingent call and/or put options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under the amendments in this update is required to assess the embedded call and/or put options solely in accordance with the four-step decision sequence. The amendments in this update are effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years, and the entity should apply the amendments on a modified retrospective basis to existing debt instruments as of the beginning of the fiscal year for which the amendments are effective. Adoption of this guidance is not expected to have a significant impact on the Company's financial position or results of operations. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which supersedes the leases requirements in Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases in accordance with FASB Concepts Statement No. 6, Elements of Financial Statements, and, therefore, recognition of those lease assets and lease liabilities represents an improvement over previous GAAP, which did not require lease assets and lease liabilities to be recognized for most leases. A qualitative disclosure along with specific quantitative disclosures is required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities. Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients that entities may elect to apply. The amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application of the amendments in this update is permitted for all entities. Chemours is currently evaluating the impact of adopting this guidance on its financial position, results of operations and debt covenants. In May 2015, the FASB issued ASU No. 2015-07, “Fair Value Measurement (Topic 820) - Disclosures for Investment in Certain Entities that Calculate Net Asset Value per Share or its Equivalent.” This guidance removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The guidance also removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The amendment is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. A reporting entity should apply the amendments retrospectively to all periods presented and earlier application is permitted. Chemours adopted this guidance effective January 1, 2016. The adoption did not have a significant effect on our financial position or results of operations. In April 2015, the FASB issued ASU 2015-05, “Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement,” which provides guidance about whether a cloud computing arrangement includes a software license. The customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. Chemours adopted this guidance effective January 1, 2016 prospectively to all arrangements entered into or materially modified after the effective date. The adoption did not have a significant impact on our financial position or results of operations. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis.” The amendments modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities and eliminate the presumption that a general partner should consolidate a limited partnership. The amendment is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Chemours adopted this guidance effective January 1, 2016 and the adoption did not change our consolidated entities, and therefore had no effect on our financial position, results of operations and cash flows. In June 2014, the FASB issued ASU No. 2014-12, “Compensation-Stock Compensation (Topic 718),” which requires an entity to treat a performance target that affects vesting and that could be achieved after the requisite service period as a performance condition in accordance with existing guidance in Topic 718. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Chemours adopted this guidance, effective January 1, 2016, prospectively to all awards granted or modified after the effective date. The adoption did not have a significant effect on our financial position or results of operations.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

Relationship with DuPont and Related Entities	6 Months Ended
Relationship with DuPont and Related Entities	Jun. 30, 2016
Related Party Transactions [Abstract]
Relationship with DuPont and Related Entities	Relationship with DuPont and Related Entities Prior to the separation, including the three and six months ended June 30, 2015, Chemours sold finished goods to DuPont and its non-Chemours businesses. Related party sales to DuPont recorded by Titanium Technologies, Fluoroproducts and Chemical Solutions for the three months ended June 30, 2015 were $1, $16 and $11, respectively, and for the six months ended June 30, 2015 were $2, $34, and $21, respectively. Subsequent to the separation, beginning on July 1, 2015, transactions with DuPont businesses were not considered related party transactions. Also prior to the separation, DuPont incurred significant corporate costs for services provided to Chemours as well as other DuPont businesses. These costs included expenses for information systems, accounting, other financial services such as treasury and audit, purchasing, human resources, legal, facilities, engineering, corporate research and development, corporate stewardship, marketing and business analysis support. A portion of these costs benefited multiple or all DuPont businesses, including Chemours, and were allocated to Chemours and its reportable segments using methods based on proportionate formulas involving total costs or other various allocation methods that management considered consistent and reasonable. Other Chemours corporate costs are not allocated to the reportable segments and are reported in Corporate and Other. The allocated leveraged functional service expenses and general corporate expenses included in the Interim Consolidated Statements of Operations were $116 and $238 for the three and six months ended June 30, 2015, respectively, and were recorded within cost of goods sold, selling, general and administrative expense and research and development expense for $10, $100 and $6, respectively, for the three months ended June 30, 2015 and $23, $205, and $10, respectively, for the six months ended June 30, 2015. Subsequent to the separation on July 1, 2015, transactions with DuPont businesses were not considered related party transactions. Accordingly, no costs from DuPont were allocated to Chemours for the three and six months ended June 30, 2016. Cash Management and Financing The separation agreements set forth a process to true-up cash and working capital transferred to us from DuPont at separation. In January 2016, Chemours and DuPont entered into an agreement, contingent upon the credit agreement amendment (described in Note 15), which provided for the extinguishment of payment obligations of cash and working capital true-ups previously contemplated in the separation agreements. As a result, Chemours was not required to make any payments to DuPont, nor did DuPont make any payments to Chemours. In addition, the agreement set forth an advance payment by DuPont of approximately $190, which Chemours received in February 2016, for certain specified goods and services that Chemours expects to provide to DuPont over twelve to fifteen months under existing agreements between the parties. The advance payment was recorded as deferred liability included in other accrued liabilities of the Interim Consolidated Balance Sheets and approximately $131 remain outstanding as of June 30, 2016. Tax Matters Agreement Chemours and DuPont entered into a tax matters agreement that governs the parties’ respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. In general, under the agreement, DuPont is responsible for any U.S. federal, state and local taxes (and any related interest, penalties or audit adjustments) reportable on a consolidated, combined or unitary return that includes DuPont or any of its subsidiaries and Chemours and/or any of its subsidiaries for any periods or portions thereof ending on or prior to the date of the separation and Chemours is responsible for any U.S. federal, state, local and foreign taxes (and any related interest, penalties or audit adjustments) that are imposed on Chemours and/or any of its subsidiaries for all tax periods, whether before or after the date of the separation.

Employee Separation and Asset Related Charges, Net

6 Months Ended

Jun. 30, 2016

Restructuring Charges [Abstract]

Employee Separation and Asset Related Charges, Net

For the three and six months ended June 30, 2016 and 2015, Chemours recorded charges for employee separation and other restructuring related charges as follows:



	Three months ended June 30,					Six months ended June 30,
	2016			2015		2016		2015
Employee separation (credit) charges	$	(2	)	$	61	$	2	$	61
Decommissioning and other charges	11			—		25		—
Asset related charges - Impairment ¹	58			—		58		—
Total	$	67		$	61	$	85	$	61


¹	Represents an asset impairment in connection with the sale of the Sulfur business. See Note 6 for further information.

The restructuring program charges impacted segment earnings for the three and six months ended June 30, 2016 and 2015 as follows:



	Three months ended June 30,					Six months ended June 30,
	2016			2015		2016		2015
Plant and product line closures
Titanium Technologies	$	9		$	—	$	18	$	—
Fluoroproducts	1			—		5		—
Chemical Solutions	(1		)	—		—		—
Total	$	9		$	—	$	23	$	—

2015 Global restructuring ¹
Titanium Technologies	$	—		$	23	$	2	$	23
Fluoroproducts	—			25		2		25
Chemical Solutions	—			13		—		13
Total	$	—		$	61	$	4	$	61

¹ Includes approximately $13 related to Corporate overhead functions that was allocated to our segments for the three and six months ended June 30, 2015.

As a result of the decommissioning and dismantling activities due to the closure of the Edge Moor manufacturing plant in the U.S., the Company recorded charges of approximately $9 and $18 for the three and six months ended June 30, 2016, respectively, in the Titanium Technology segment. The decommissioning, dismantling and removal activities will continue for the remainder of 2016 through early 2017 and the Company expects to incur additional charges of approximately $30, which will be expensed as incurred.

The Company's Fluoroproducts segment also recorded charges of approximately $1 and $5 for the three and six months ended June 30, 2016, respectively, related to decommissioning, dismantling and removal activities on certain of its production lines in the U.S. The Company also expects to incur an additional $5 for dismantling and removal costs in the remainder of 2016 through early 2017, which will be expensed as incurred.

The plant and product line closures for Titanium Technologies and Fluoroproducts segments were implemented in the third quarter of 2015. As such, no restructuring related expenses were incurred in the three and six months ended June 30, 2015.

Prior to the separation, in the second quarter of 2015, the Company implemented a restructuring plan, which resulted in a global workforce reduction of more than 430 positions and a pre-tax charge of $61 for employee separation costs in the three and six months ended June 30, 2015. The actions associated with these charges and related payments are substantially completed at June 30, 2016.

After the separation, in the fourth quarter 2015, the Company announced an additional global workforce reduction as part of its ongoing efforts to streamline and simplify its organizational structure and reduce costs. The Company incurred an additional $4 of employee separation costs for the six months ended June 30, 2016 in connection with this restructuring plan. The actions associated with these charges are expected to be completed by the end of 2016 and related payments are expected to be substantially complete in 2017.

The following table shows the change in the employee separation related liability account associated with the restructuring programs:



	Titanium Technologies Site Closures			Fluoroproducts Lines Shutdown			Chemical Solutions Site Closures			2015 Global Restructuring			Total
Balance as of December 31, 2015	$	11		$	2		$	12		$	73		$	98
Charges (credits) to income for the six months ended June 30, 2016 ¹	—			—			(2		)	4			2
Charges to liability accounts:
Payments	(4		)	(1		)	—			(36		)	(41		)
Net currency translation and other adjustment ²	—			—			—			—			—
Balance as of June 30, 2016	$	7		$	1		$	10		$	41		$	59


¹	Due to unexpected resignations of certain employees at the Company's Niagara site, approximately $2 of employee separation charges, related to the Chemical Solutions Niagara site closure action announced in the fourth quarter of 2015, were reversed to income in the three and six months ended June 30, 2016.


²	Net currency translation adjustment was less than $1 for the period presented.

There are no significant outstanding liabilities related to the decommissioning and other restructuring related charges.

Sales of Assets and Businesses

6 Months Ended

Jun. 30, 2016

Discontinued Operations and Disposal Groups [Abstract]

Sales of Assets and Businesses

On June 13, 2016, the Company entered into an asset purchase agreement with Veolia North America, (“Veolia”), pursuant to which Veolia agreed to acquire Chemours’ Sulfur Products business (“Sulfur business”) of its Chemical Solutions segment for a purchase price of $325 in cash, subject to customary working capital and other adjustments, of which approximately $10 was received in May 2016. As a result, as of June 30, 2016, the related assets of the Sulfur business of approximately $339 were classified as held-for-sale on the Interim Consolidated Balance Sheets, net of an impairment loss of approximately $58 which was recorded for the period ended June 30, 2016 in “Employee separation and asset related charges, net” related to this transaction. The approximately $10 proceeds were recorded in “Other current liabilities” on the Interim Consolidated Balance Sheets. The Company completed the sale and received the remaining proceeds of approximately $311 on July 29, 2016, net of estimated working capital adjustments. The completion of the sale is also subject to certain customary post-closing conditions and other adjustments.

On April 22, 2016, the Company entered into a stock and asset purchase agreement with LANXESS Corporation, (“Lanxess”), pursuant to which Lanxess agreed to acquire Chemours’ Clean & Disinfect product line (the “C&D business”) of its Chemical Solutions segment by acquiring certain Chemours' subsidiaries, including a guarantor subsidiary, and assets comprising the C&D business for a purchase price of $230 in cash, subject to customary working capital and other adjustments. As a result, as of June 30, 2016, the C&D business’ assets of approximately $39, including goodwill of approximately $13, and liabilities of approximately $4 were classified as held-for-sale on the Interim Consolidated Balance Sheets. The $4 of liabilities held-for-sale were included within the caption “Other accrued liabilities”. The Company expects to record a pre-tax gain of approximately $185 (subject to customary working capital and other adjustments) when the transaction closes, which is expected to occur in the second half of 2016. The completion of the transaction is subject to certain customary closing conditions and regulatory approvals.

In November 2015, the Company signed a definitive agreement to sell its aniline facility in Beaumont, Texas to The Dow Chemical Company (Dow). The transaction closed on March 1, 2016 and Chemours received $140 in cash from Dow. The net book value of the assets disposed was $41, which includes inventories, property, plant and equipment, other assets and allocated goodwill, and the Company incurred approximately $11 of transaction and other related charges. As a result, for the six months ended June 30, 2016, Chemours recognized a pre-tax gain of approximately $88 in the Chemical Solutions segment.

The major components of assets held-for-sale are as follows:



	June 30, 2016			December 31, 2015
Current assets:
Accounts receivables	$	21		$	—
Inventories	5			5
Total current assets	26			5
Property, plant and equipment, net	260			30
Goodwill	13			4
Other assets	137			7
Less: Impairment loss	(58		)	—
Total non-current assets, net	352			41
Total assets held-for-sale, net	$	378		$	46

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

Other Income (Expense), Net

6 Months Ended

Jun. 30, 2016

Other Income and Expenses [Abstract]

Other Income (Expense), Net



	Three months ended June 30,					Six months ended June 30,
	2016			2015		2016			2015
Leasing, contract services and miscellaneous income ¹	$	5		$	—	$	12		$	4
Royalty income²	6			2		9			7
(Loss) gain on sale of assets and business ³	(1		)	—		88			—
Exchange (losses) gains, net ⁴	(14		)	19		(20		)	3
Total other (expense) income, net	$	(4	)	$	21	$	89		$	14

¹Miscellaneous income includes accrued interest related to unrecognized tax benefits.

²Royalty income is primarily for technology and trademark licensing.

³The six months ended June 30, 2016 includes gain on sale of the aniline facility in Beaumont, TX. See Note 6 for additional information.

⁴Exchange losses, net includes gains and loss on foreign currency forward contracts. See Note 17 for additional information.

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended June 30, 2016 and 2015, Chemours recorded a tax benefit of $23 and $0, respectively, or an effective income tax rate of approximately 56% and 0%, respectively. For the six months ended June 30, 2016 and 2015, Chemours recorded a benefit from income tax of $5 and a provision for income tax of $15 or an effective income tax rate of negative 18% and 38%, respectively. The $23 and $20 increases in tax benefits for the three and six months ended June 30, 2016, respectively, and the corresponding changes in the effective income tax rates were primarily due to the geographical mix of earnings. Restructuring charges and asset impairment, most of which occurred in the United States, resulted in an increase in tax benefit and a corresponding change in the effective income tax rate for 2016 as compared to 2015. In addition, the increase in tax benefit for the six months ended June 30, 2016 was partially offset by the gain on sale of the aniline facility in the U.S.

Earnings Per Share of Common Stock

6 Months Ended

Jun. 30, 2016

Earnings Per Share [Abstract]

Earnings Per Share of Common Stock

The table below shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated:



	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016		2015
Numerator:
Net (loss) income attributable to Chemours	$	(18	)	$	(18	)	$	33	$	25
Denominator:
Weighted-average number of common shares outstanding - Basic ¹	181,477,672			180,966,833			181,379,419		180,966,833
Dilutive effect of the company's employee compensation plans²	—			—			668,410		—
Weighted average number of common shares outstanding - Diluted ²	181,477,672			180,966,833			182,047,829		180,966,833

¹For June 30, 2015, pro forma earnings per share was calculated based on 180,966,833 shares of Chemours common stock that were distributed to DuPont shareholders on July 1, 2015.

²Diluted earnings per share is calculated using net income available to common shareholders divided by diluted weighted-average shares of common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

The following average number of stock options were antidilutive and, therefore, were not included in the diluted earnings per share calculation:



	Three months ended June 30,		Six months ended June 30,
	2016	2015	2016	2015
Average number of stock options	7,356,050	—	8,028,762	—

Accounts and Notes Receivable - Trade, Net

6 Months Ended

Jun. 30, 2016

Receivables [Abstract]

Accounts and Notes Receivable - Trade, Net

Accounts and Notes Receivable – Trade, Net



	June 30, 2016		December 31, 2015
Accounts receivable—trade, net ¹	$	849	$	759
VAT, GST and other taxes ²	74		68
Leases receivable—current ³	—		13
Other receivables ⁴	16		19
Total	$	939	$	859


¹	Accounts receivable – trade, net includes trade notes receivable and is net of allowances of $4 and $4 as of June 30, 2016 and December 31, 2015, respectively. Allowances are equal to the estimated uncollectible amounts.


²	Value Added Tax (VAT) and Goods and Services Tax (GST).


³	See Note 14 for information relating to direct financing leases.


⁴	Other receivables consist of advances and other deposits.

Accounts and notes receivable are carried at amounts that approximate fair value. Bad debt expense was less than $1 for the three and six months ended June 30, 2016 and 2015.

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

6 Months Ended

Jun. 30, 2016

Inventory, Net [Abstract]

Inventories



	June 30, 2016			December 31, 2015
Finished products	$	628		$	613
Semi-finished products	169			172
Raw materials, stores and supplies	332			433
Subtotal	1,129			1,218
Adjustment of inventories to a last-in, first-out (LIFO) basis	(237		)	(246		)
Total	$	892		$	972

Inventory values, before LIFO adjustment, are generally determined by the average cost method, which approximates current cost. Inventories are valued under the LIFO method at substantially all of the U.S. locations, which comprised $640 and $744 or 57% and 61% of inventories before the LIFO adjustments at June 30, 2016 and December 31, 2015, respectively. The remainder of inventory held in international locations and certain U.S. locations is valued under the average cost method.

Property, Plant, and Equipment	6 Months Ended
Property, Plant, and Equipment	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Depreciation expense amounted to $73 and $138 for the three and six months ended June 30, 2016, respectively, and $66 and $129 for the three and six months ended June 30, 2015, respectively. Property, plant and equipment includes gross assets under capital leases of $7 at June 30, 2016 and December 31, 2015.

Goodwill and Other Intangible Assets, Net

6 Months Ended

Jun. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets, Net

Goodwill: The following table summarizes changes in the carrying amount of goodwill by reportable segment:



	Titanium Technologies		Fluoroproducts		Chemical Solutions			Total
Balance as of December 31, 2015	$	13	$	85	$	68		$	166
Asset held-for-sale ¹	—		—		(13		)	(13		)
Currency translation adjustment ²	—		—		—			—
Balance as of June 30, 2016	$	13	$	85	$	55		$	153


¹	Represents the reclassification of goodwill to assets held-for-sale in connection with the sale of the C&D business (See Note 6).


²	Net currency translation adjustment was less than $1 for the period presented.

Other Intangible Assets, Net: The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class:



	June 30, 2016							December 31, 2015
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer lists	$	12	$	(10	)	$	2	$	13	$	(10	)	$	3
Patents	19		(17		)	2		19		(17		)	2
Purchased trademarks	5		(2		)	3		5		(2		)	3
Purchased and licensed technology	3		(2		)	1		8		(6		)	2
Total	$	39	$	(31	)	$	8	$	45	$	(35	)	$	10

The aggregate amortization expense for definite-lived intangible assets was $1 for the three and six months ended June 30, 2016, respectively, and $1 and $2 for the three and six months ended June 30, 2015, respectively. Definite-lived intangible assets are amortized over their estimated useful lives, generally for periods ranging from 5 to 20 years. There are no material indefinite-lived intangible assets.

The estimated amortization for the remainder of 2016 and each of the succeeding four years is:



Remainder of 2016	$	1
2017	2
2018	1
2019	1
2020	1

Other Assets

6 Months Ended

Jun. 30, 2016

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Assets



	June 30, 2016		December 31, 2015
Leases receivable - non-current ¹	$	—	$	125
Capitalized repair and maintenance costs	111		149
Pension assets ²	164		138
Deferred income taxes - non-current	46		47
Miscellaneous ³	48		49
Total	$	369	$	508


¹	Relates to Sulfur business which was reclassified to assets held-for-sale as of June 30, 2016. See Direct Financing Leases below.

²Pension assets represent the funded status of certain of the Company's long-term employee benefit plans.

³Miscellaneous includes deferred financing fees related to the Revolving Credit Facility of $15 and $19 as of June 30, 2016 and December 31, 2015, respectively.

Direct Financing Leases

At two of its facilities in the U.S. (Borderland and Morses Mill), Chemours has constructed fixed assets on land that it leases from third parties. Management has analyzed these arrangements and determined these assets represent a direct financing lease, whereby Chemours is the lessor of this equipment. Chemours has recorded leases receivable of $131 and $138 at June 30, 2016 and December 31, 2015 respectively, which represent the balance of the minimum future lease payments receivable. The current portion of leases receivable was previously included in accounts and notes receivable - trade, net, as shown in Note 10. The long-term portion of leases receivable was previously included in other assets, as shown above. These lease receivables have been included in the sale of the Sulfur business as discussed in Note 6, and were reclassified as assets held-for-sale as of June 30, 2016.

Debt

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Debt

Long-term debt was comprised of the following at June 30, 2016 and December 31, 2015:



	June 30, 2016		December 31, 2015
Long-term debt:
Senior secured term loan	$	1,435	$	1,493
Senior unsecured notes:
6.625%, due May 2023	1,308		1,350
7.00%, due May 2025	750		750
6.125%, due May 2023 (€360)	398		395
Other	23		26
Total	3,914		4,014
Less: Unamortized issue discount on senior secured term loan	6		7
Less: Unamortized debt issuance costs	49		53
Less: Current maturities	36		39
Total long-term debt	$	3,823	$	3,915

Senior Secured Credit Facilities

During the first quarter of 2016, Chemours and its Revolving Credit Facility lenders entered into a second amendment to the credit agreement that (a) replaced the total net leverage ratio financial covenant with a senior secured net leverage ratio financial covenant; (b) reduced the minimum levels required by the interest expense coverage ratio covenant; (c) increased the limits and extended the period of adding back the benefits of announced cost reduction initiatives in the determination of Consolidated EBITDA for the purposes of calculating the financial maintenance covenants; and (d) reduced the revolver commitment from $1,000 to $750. As a result of the amendment, the Company recorded a charge of approximately $4 to write off a proportionate amount of unamortized debt issuance costs attributable to the reduction in revolver commitment, which was included in interest expense, net. Fees and expenses of approximately $2 incurred in connection with the amendment were capitalized in other assets of the Interim Consolidated Balance Sheets, which will be amortized to interest expense on a straight-line basis over the remaining term of the Revolving Credit Facility.

The credit agreement contains financial covenants which, solely with respect to the Revolving Credit Facility as amended, require Chemours not to exceed a maximum senior secured net leverage ratio of 3.50 to 1.00 each quarter through December 31, 2016, 3.00 to 1.00 through June 30, 2017 and further decreasing by 0.25 to 1.00 every subsequent six months to 2.00 to 1.00 by January 1, 2019 and thereafter. Chemours is also required to maintain a minimum interest coverage ratio of 1.75 to 1.00 each quarter through June 30, 2017 and further increasing by 0.25 to 1.00 every subsequent six months to 3.00 to 1.00 by January 1, 2019 and thereafter. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict Chemours and its subsidiaries' ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default. Chemours was in compliance with its debt covenants as of June 30, 2016.

During the second quarter 2016, the Company repurchased through open market transactions an aggregate principal amount of $50 of its senior secured term loans for $49 in cash. We recorded in “interest expense, net” of the Interim Consolidated Statements of Operations less than $1 gain on extinguishment of debt, net of approximately less than $1 charge related to the write-off of deferred financing costs and issue discount associated with the extinguished debt.

Senior Unsecured Notes

Chemours entered into a registration rights agreement in connection with the issuance on May 12, 2015 of $1,350 aggregate principal amount of its 6.625% Senior Notes due 2023 (the “2023 Notes”), $750 aggregate principal amount of its 7.000% Senior Notes due 2025 (the “2025 Notes”) and €360 aggregate principal amount of its 6.125% Senior Notes due 2023 (the “Euro Notes,” and together with the 2023 Notes and the 2025 Notes, the “Notes”). Under the registration rights agreement, Chemours agreed to file with the SEC within 465 days after the original issue date of the Notes a registration statement for the exchange offer of the Notes for new registered notes with identical terms. Chemours filed with the SEC a registration statement on Form S-4 with respect to the exchange offer on March 18, 2016, which was declared effective on April 12, 2016, and the exchange offer was completed on May 19, 2016. In addition, on May 5, 2016, the Euro Notes were admitted to listing on the Official List and trading on the Global Exchange Market of the Irish Stock Exchange.

During the second quarter 2016, the Company repurchased through open market transactions an aggregate principal amount of $42 of its 2023 Notes for $36 in cash. We recorded in “interest expense, net” of the Consolidated Statements of Operations a $5 gain on extinguishment of debt, net of approximately $1 charge related to the write-off of deferred financing costs associated with the extinguished debt.

Maturities

There are no debt maturities prior to year 2022, except, in accordance with the credit agreement, Chemours has required quarterly principal payments related to the Term Loan Facility equivalent to 1.00% per annum beginning September 2015 through March 2022, with the balance due at maturity. Term Loan principal maturities over the next five years are $8 for the remainder of 2016 and $15 in each year from 2017 to 2021. Debt maturities related to the Term Loan Facility and the Notes in 2022 and beyond will be $3,808.

In addition, following the end of each fiscal year commencing on the year ended December 31, 2016, the Company is also required to make additional principal repayments as defined in the credit agreement, depending on leverage level, equivalent to up to 50% of excess cash flow based on certain leverage targets with stepdowns to 25% and 0% as actual leverage decreases.

Debt Fair Value

The fair values of the Term Loan Facility, the 2023 Notes, the 2025 Notes and the Euro Notes at June 30, 2016 were approximately $1,392, $1,105, $628 and $312, respectively. The estimated fair values of the Term Loan Facility and the Notes are based on quotes received from third party brokers, and are classified as Level 2 in the fair value hierarchy.

Commitments and Contingent Liabilities

6 Months Ended

Jun. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingent Liabilities

(a) Guarantees

Chemours has directly guaranteed various obligations of customers, suppliers and other third parties. As of June 30, 2016 and December 31, 2015, the maximum potential amount of future (undiscounted) payments that Chemours could be required to make under the guarantees in the event of default by the guaranteed parties is approximately $8. No amounts were accrued at June 30, 2016 and December 31, 2015.

(b) Litigation

In addition to the matters discussed below, Chemours, by virtue of its status as a subsidiary of DuPont prior to the separation, is subject to or required under the separation-related agreements executed prior to the separation to indemnify DuPont against various pending legal proceedings arising out of the normal course of the Chemours business including product liability, intellectual property, commercial, environmental and antitrust lawsuits. It is not possible to predict the outcome of these various proceedings. Except for the PFOA litigation for which a separate assessment is provided in this Note, while management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on Chemours' consolidated financial position, results of operations or liquidity. With respect to the litigation matters discussed below, including PFOA litigation, management's estimate of the probability of loss in excess of the amounts accrued, if any, is addressed individually for each matter. In the event that DuPont seeks indemnification for adverse trial rulings or outcomes for any such matter relating to PFOA, these indemnification claims could materially adversely affect Chemours' financial condition. Disputes between Chemours and DuPont may also arise with respect to indemnification matters, including disputes based on matters of law or contract interpretation, or related to the type of damages or liabilities for which indemnification may be sought. If and to the extent these disputes arise, they could materially adversely affect Chemours.

Asbestos

At June 30, 2016 and December 31, 2015, there were approximately 1,979 lawsuits and 2,212 lawsuits, respectively, pending against DuPont alleging personal injury from exposure to asbestos. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. A small number of cases are pending outside the U.S. Most of the actions were brought by contractors who worked at sites between 1950 and the 1990s. A small number of cases involve similar allegations by DuPont employees. A limited number of the cases were brought by household members of contractors or DuPont employees. Finally, certain lawsuits allege personal injury as a result of exposure to DuPont products. At June 30, 2016 and December 31, 2015, Chemours had an accrual of $44 related to this matter. Chemours reviews this estimate and related assumptions quarterly and annually updates the results of an approximate 20-year projection. Management believes that the likelihood is remote that Chemours would incur losses in excess of the amounts accrued in connection with this matter.

Benzene

In the separation, DuPont assigned its Benzene docket to Chemours. At June 30, 2016 and December 31, 2015, there are 28 and 29, respectively, pending cases against DuPont alleging benzene-related illnesses. These cases consist of premises matters involving contractors and deceased former employees who claim exposure to benzene while working at DuPont sites primarily in the 1960s through the 1980s, and product liability claims based on alleged exposure to benzene found in trace amounts in aromatic hydrocarbon solvents used to manufacture DuPont products, such as paints, thinners and reducers.

A benzene case (Hood v. DuPont) was tried to a verdict in Texas state court on October 20, 2015. Plaintiffs alleged that Mr. Hood's Acute Myelogenous Leukemia (AML) was the result of 24 years of occupational exposure to trace benzene found in DuPont automotive paint products and that DuPont negligently failed to warn him that its paints, reducers and thinners contained benzene that could cause cancer or leukemia. The jury found in the Plaintiffs favor awarding $6.9 in compensatory damages and $1.5 in punitive damages. In March 2016, acting on the Company's motion, the Court struck the punitive award. Through DuPont, Chemours has filed an appeal on the remaining award based upon substantial errors made at the trial court. Plaintiffs have filed a cross appeal. Management believes that a loss is reasonably possible related to these matters; however, given the evaluation of each Benzene matter is highly fact driven and impacted by disease, exposure and other factors, a range of such losses cannot be reasonably estimated at this time.

PFOA

Prior to the fourth quarter of 2014, the performance chemicals segment of DuPont made PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) at its Fayetteville plant (Fayetteville, North Carolina) and used PFOA as a processing aid in the manufacture of fluoropolymers and fluoroelastomers at certain sites including: Washington Works (Parkersburg, West Virginia), Chambers Works (Deepwater, New Jersey), Dordrecht Works (Netherlands), Changshu Works (China), and Shimizu (Japan). These sites are now owned and/or operated by Chemours.

Chemours had accruals of $19 and $20 related to the PFOA matters discussed below at June 30, 2016 and December 31, 2015, respectively. The accruals include charges related to DuPont’s obligations under agreements with the U.S. Environmental Protection Agency (EPA) and voluntary commitments to the New Jersey Department of Environmental Protection (NJDEP). These obligations and voluntary commitments include surveying, sampling and testing drinking water in and around certain company sites offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national Health Advisory. A provisional health advisory level was set in 2009 at 0.4 parts per billion (ppb) that includes PFOA in drinking water. In May 2016, the EPA announced a health advisory level of 0.07 ppb that includes PFOA in drinking water. As a result, we recorded an additional $4 during the three months ended June 30, 2016 based on management's best estimate of the impact of the new health advisory level on the company’s obligations to the EPA, which have expanded the testing and water supply commitments previously established. Based on prior testing, the Company has initiated additional testing and treatment in certain additional locations in and around Chambers Works and Washington Works plants. The Company will continue to work with the EPA regarding the extent of work that may be required with respect to these matters.

Drinking Water Actions

In August 2001, a class action, captioned Leach v. DuPont, was filed in West Virginia state court alleging that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water.

DuPont and attorneys for the class reached a settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the plaintiffs’ attorneys’ fees and expenses of $23 and made a payment of $70, which class counsel designated to fund a community health project. Chemours, through DuPont, funded a series of health studies which were completed in October 2012 by an independent science panel of experts (the C8 Science Panel). The studies were conducted in communities exposed to PFOA to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and human disease. The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis and diagnosed high cholesterol.

In May 2013, a panel of three independent medical doctors released its initial recommendations for screening and diagnostic testing of eligible class members. In September 2014, the medical panel recommended follow-up screening and diagnostic testing three years after initial testing, based on individual results. The medical panel has not communicated its anticipated schedule for completion of its protocol. Through DuPont, Chemours is obligated to fund up to $235 for a medical monitoring program for eligible class members and, in addition, administrative cost associated with the program, including class counsel fees. In January 2012, Chemours, through DuPont, put $1 in an escrow account to fund medical monitoring as required by the settlement agreement. The court-appointed Director of Medical Monitoring has established the program to implement the medical panel’s recommendations and the registration process, as well as eligibility screening, is ongoing. Diagnostic screening and testing has begun and associated payments to service providers are being disbursed from the escrow account. As of June 30, 2016, less than $1 has been disbursed from the escrow account related to medical monitoring.

In addition, under the settlement agreement, DuPont must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts and private well users. At separation, this obligation was assigned to Chemours, which is included in the accrual amounts recorded as of June 30, 2016.

Class members may pursue personal injury claims against DuPont only for those human diseases for which the C8 Science Panel determined a probable link exists. At June 30, 2016 and December 31, 2015, there were approximately 3,500 lawsuits filed in various federal and state courts in Ohio and West Virginia, an increase of approximately 600 over year end 2014. These lawsuits are consolidated in multi-district litigation (MDL) in Ohio federal court. Based on the information currently available to the Company, the majority of the lawsuits allege personal injury claims associated with high cholesterol and thyroid disease from exposure to PFOA in drinking water. There are 30 lawsuits alleging wrongful death.

Although the majority of the plaintiffs in the MDL allege multiple diseases, the table below approximates the number of plaintiffs in each of the six probable link disease categories.



Alleged Injury	Approximate Number of Plaintiffs
Kidney cancer	200
Testicular cancer	70
Ulcerative colitis	300
Preeclampsia	200
Thyroid disease	1,430
High cholesterol	1,340

In the third quarter of 2014, six plaintiffs from the MDL were selected for individual bellwether trials.

All six bellwether cases in the MDL have now been tried, resolved, appealed or otherwise addressed. Two bellwether cases have been tried. The first case (Bartlett v. DuPont / kidney cancer) was tried to a verdict in October 2015. The jury found in favor of the plaintiff, awarding $1.1 in damages for negligence and $0.5 for emotional distress. The jury found that DuPont’s conduct did not warrant punitive damages. A second case (Freeman v. DuPont / testicular cancer) was tried to verdict in July 2016. The jury found in favor of the plaintiff awarding $5.1 in compensatory damages and $0.5 in punitive damages and attorneys’ fees. Court rulings made before and during both trials resulted in several significant grounds for appeal and an appeal to the Sixth Circuit has been filed for the first case. The Company, through DuPont, will pursue post-trial motions and appeals for the second case.

Three bellwether PFOA cases were settled in 2016 as trial approached. These cases (Wolf v. DuPont / ulcerative colitis, Dowdy v. DuPont / kidney cancer, Baker v. DuPont / kidney cancer) were settled for amounts well below the incremental cost of preparing for trials. To date, the settlements have been individually and in aggregate immaterial to the Company. The final case (Pugh v. DuPont / ulcerative colitis) was removed from the bellwethers when it was determined that the plaintiff did not suffer from the alleged disease.

The trial court announced that, starting in May 2017, 40 individual plaintiff trials will be scheduled for a 12-month period. With the conclusion of the six bellwether cases, the court moved two of the 40 matters (Vigneron v. DuPont / testicular cancer and Moody v. DuPont / testicular cancer) forward on July 19, 2016 and set the cases for trial on November 14, 2016 and January 17, 2017, respectively. The trial court’s multi-year plan pertains only to the approximately 270 cases claiming cancer. The remaining cases, comprising approximately 93% of the docket, will remain inactive.

A confidential mediation process that the court established early in this MDL is ongoing and expected to continue as the litigation proceeds.

Chemours, through DuPont, denies the allegations in these lawsuits and is defending itself vigorously. No other claims have been settled or resolved during the periods presented. DuPont is the named defendant in each of these cases and is directly liable for any judgment. If DuPont were to claim that it is entitled to indemnification from Chemours as to some or all of any judgment, Chemours retains its defenses to such claims.

PFOA Summary

While it is probable that the Company will incur costs related to the medical monitoring program discussed above, such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing. Chemours believes that it is probable that it could incur losses related to the MDL in Ohio federal court discussed above but a range of such losses cannot be reasonably estimated at this time. Given the wide range of outcomes associated with the six initial cases in the MDL as discussed above, including two cases that have been or will be appealed, the Company does not believe activity to date provides a reasonable basis to derive a range of loss for the remaining lawsuits still pending in the MDL in total or by category of claim. The possible range of loss is unpredictable and involves significant uncertainty due to the uniqueness of the individual MDL plaintiff's claims and the defenses to those claims, both as to potential liability and damages on an individual claim basis, and numerous unsettled legal issues, among other factors, such as general versus specific causation, lack of specific fact discovery allowed to date on vast majority of the cases, lack of validation of basic facts associated with plaintiffs and related claims, and the two bellwether cases tried to verdict to date did not inform of the many salient facts and legal issues needed for assessment of the other cases. The appellate courts will rule on both matters that have been tried. The Company believes there are strong common and individual grounds for appealing these verdicts and, if any such verdict is overturned, any subsequent verdict relying on such overturned ruling would likely also be overturned. In addition, as noted above, Chemours retains its defenses to related indemnification claims that may be received from DuPont. The trials and appeals of the MDL matters will occur over the course of many years. Significant unfavorable outcomes in a number of cases in the MDL could have a material adverse effect on Chemours' consolidated financial position, results of operations or liquidity.

Chemours, by virtue of its status as a subsidiary of DuPont prior to the separation, is subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances by Chemours or other parties. Chemours accrues for environmental remediation activities consistent with the policy set forth in Note 3 to the consolidated financial statements in our Annual Report on Form 10-K. Much of this liability results from the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA, often referred to as Superfund), RCRA and similar state and global laws. These laws require Chemours to undertake certain investigative, remediation and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

At June 30, 2016 and December 31, 2015, the Interim Consolidated Balance Sheets included a liability of $290 relating to these matters which, in management’s opinion, is appropriate based on existing facts and circumstances. The average time frame over which the accrued or presently unrecognized amounts may be paid, based on past history, is estimated to be 15 to 20 years. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of other potentially responsible parties. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, the potential liability may range up to approximately $600 above the amount accrued at June 30, 2016. Except for Pompton Lakes, which is discussed further below, based on existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on the financial position, liquidity or results of operations of Chemours.

Pompton Lakes

At June 30, 2016 and December 31, 2015, the environmental remediation accruals related to activities at Chemours’ site in Pompton Lakes, New Jersey were $86 and $87, respectively. Management believes that it is reasonably possible that remediation activities at this site could range up to $119 including previously accrued amounts. This could have a material impact on the liquidity of Chemours in any given period if recognized. However, management does not believe this would have a material adverse effect on Chemours' overall financial condition, liquidity or results of operations. During the twentieth century, blasting caps, fuses and related materials were manufactured at Pompton Lakes. Operating activities at the site were ceased in the mid-1990s. Primary contaminants in the soil and sediments are lead and mercury. Ground water contaminants include volatile organic compounds.

Under the authority of the EPA and the NJDEP, remedial actions at the site are focused on investigating and cleaning up the area. Ground water monitoring at the site is ongoing and Chemours, through DuPont, has installed and continues to install vapor mitigation systems at residences within the ground water plume. In addition, Chemours is further assessing ground water conditions. In June 2015, the EPA issued a modification to the site's RCRA permit that requires Chemours to dredge mercury contamination from a 36 acre area of the lake and remove sediment from two other areas of the lake near the shoreline. Chemours expects to spend about $50 over the next two to three years, which is included in the remediation accrual as of June 30, 2016, in connection with remediation activities at Pompton Lakes, including activities related to the EPA’s final plan. The remediation activities commenced when permits and implementation plans were approved in May 2016.

Financial Instruments

6 Months Ended

Jun. 30, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instruments

Derivative Instruments

Foreign Currency Forward Contracts

Chemours uses foreign currency forward contracts to reduce its net exposure, by currency, related to non-functional currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. These derivative instruments are not part of a cash flow hedge program or a fair value hedge program, and have not been designated as a hedge. Although all of the forward contracts are subject to an enforceable master netting agreement, Chemours has elected to present the derivative assets and liabilities on a gross basis on the balance sheets. No collateral has been required for these contracts. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in “other income (expense), net” in the statements of operations during the period in which they occurred.

At June 30, 2016, there were 47 foreign currency forward contracts outstanding with an aggregate gross notional value of $270. Chemours recognized in “other income, net” of the Interim Consolidated Statements of Operations net gain of $1 and a net loss of $1 for the three and six months ended June 30, 2016, respectively, and net gains of $23 and $12 for the three and six months ended June 30, 2015, respectively.

Net Investment Hedge - Foreign Currency Borrowings

Beginning on July 1, 2015, Chemours designated its €360 Euro Notes (see Note 15) as a hedge of its net investments in certain of its international subsidiaries that use the Euro as functional currency in order to reduce the volatility in stockholders’ equity caused by the changes in foreign currency exchange rates of the Euro with respect to the U.S. Dollar. Chemours used the spot method to measure the effectiveness of the net investment hedge. Under this method, for each reporting period, the change in the carrying value of the Euro Notes due to remeasurement of the effective portion is reported in accumulated other comprehensive income on the balance sheet and the remaining change in the carrying value of the ineffective portion, if any, is recognized in “other income (expense), net” in the statements of operations. Chemours evaluates the effectiveness of its net investment hedge quarterly. For the three and six months ended June 30, 2016, Chemours did not record any ineffectiveness and recognized a gain of $4 and a loss of $3, respectively, on its net investment hedges in accumulated other comprehensive income (loss).

Fair Value of Derivative Instruments

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy:



		Fair Value Using Level 2 Inputs
	Balance Sheet Location	June 30, 2016		December 31, 2015
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	2	$	2
Total asset derivatives		$	2	$	2

Liability derivatives
Foreign currency forward contracts	Other accrued liabilities	$	2	$	2
Total liability derivatives		$	2	$	2

We classify our foreign currency forward contracts as Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance/quality checks.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Long-Term Employee Benefits

6 Months Ended

Jun. 30, 2016

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Long-Term Employee Benefits

The components of net periodic benefit (income) cost for all significant pension plans were as follows:



	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016			2015
Service cost	$	4		$	3		$	7		$	6
Interest cost	5			4			10			9
Expected return on plan assets	(17		)	(20		)	(33		)	(41		)
Amortization of actuarial net loss	7			3			11			7
Amortization of prior service cost (gain)	—			1			(1		)	2
Curtailment gain	(2		)	—			(2		)	—
Net periodic benefit income	$	(3	)	$	(9	)	$	(8	)	$	(17	)

The net periodic benefit income is based on estimated values and an extensive use of assumptions about the discount rate, expected return on plan assets and the rate of future compensation increases received by the Company’s employees.

Chemours made cash contributions of $5 and $9 to its pension plans during the three and six months ended June 30, 2016, respectively, and expects to make additional cash contributions of $9 to the pension plan during the remainder of 2016.

Participation in the DuPont Plans

Prior to July 1, 2015, Chemours participated in DuPont’s U.S. and non-U.S. benefit plans, except in the Netherlands and Taiwan, as though its employees were participants in a multi-employer plan with the other businesses of DuPont. As a result, for the three and six months ended June 30, 2015, Chemours recognized $26 and $53, respectively, of pension and other long-term benefit expenses allocated by DuPont based on Chemours' active employee headcount.

Stock-based Compensation

6 Months Ended

Jun. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-based Compensation

Stock-based Compensation

Total stock-based compensation cost included in the Interim Consolidated Statements of Operations was $5 and $3 for the three months ended June 30, 2016 and 2015, respectively, and $10 and $5 for the six months ended June 30, 2016 and 2015, respectively. The income tax benefits related to stock-based compensation arrangements were $2 and $1 for the three months ended June 30, 2016 and 2015, respectively, and $4 and $2 for the six months ended June 30, 2016 and 2015, respectively.

Stock-based compensation expense in prior years and until separation on July 1, 2015 was allocated to Chemours based on the portion of DuPont’s incentive stock program in which Chemours employees participated. Adopted at separation, the Chemours Equity and Incentive Plan grants certain employees, independent contractors, or non-employee directors of the Company different forms of awards, including stock options and restricted stock units (RSUs). The Equity and Incentive Plan has a maximum shares reserve of 13,500,000 for the grant of equity awards plus the number of shares of DuPont equity awards that converted into new Chemours equity awards. The Chemours Compensation Committee determines the long-term incentive mix, including stock options and RSUs, and may authorize new grants annually. As of June 30, 2016, 8,594,630 shares of the Equity and Incentive Plan reserve are still available for grants. Subject to vesting conditions of the award, a retirement eligible employee retains any granted awards upon retirement provided the employee has rendered at least six months of service following the grant date.

Stock Options

During 2016, Chemours granted non-qualified options to certain of its employees, which will serially vest over a three-year period and expire 10 years from the date of grant. The expense related to stock options granted in the six months ended June 30, 2016 was based on the weighted-average assumptions shown in the table below. No stock options were granted by Chemours in the three and six months ended June 30, 2015.



Weighted-Average Assumptions	June 30, 2016
Risk-free interest rate	1.46		%
Expected term (years)	6.00
Volatility	80.90		%
Dividend yield	2.14		%
Fair value per stock option	$	3.41

The Company determined the dividend yield by dividing the expected annual dividend on the Company's stock by the option exercise price. A historical daily measurement of volatility is determined based on the average volatility of peer companies adjusted for the Company's debt leverage. The risk-free interest rate is determined by reference to the yield on an outstanding U.S. Treasury note with a term equal to the expected life of the option granted. Expected life is determined using a simplified approach, calculated as the midpoint between the vesting period and the contractual life of the award.

The following table summarizes Chemours stock option activity for the six months ended June 30, 2016.



	Number of Shares (in thousands)		Weighted Average Exercise Price (per share)		Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2015	8,284		$	14.66	4.82	$	—
Granted	1,406		5.73
Exercised	(12	)	8.38
Forfeited	(252	)	15.46
Expired	(356	)	5.82
Outstanding, June 30, 2016	9,070		13.60		5.28	$	3,556
Exercisable, June 30, 2016	4,928		13.69		3.55	$	—

The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company's closing stock price on the last trading day of June 30, 2016 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their in-the-money options at quarter end. The amount changes based on the fair market value of the Company's stock. Total intrinsic value of options exercised for the six months ended June 30, 2016 was insignificant.

As of June 30, 2016, $6 of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted-average period of 1.78 years.

RSUs

During 2016, Chemours granted additional RSUs to key senior management employees that generally vest over a three-year period and, upon vesting, convert one-for-one to Chemours common stock. The fair value of all stock-settled RSUs is based upon the market price of the underlying common stock as of the grant date.

Non-vested awards of RSUs, both with and without a performance condition, as of June 30, 2016 are shown below.



	Number of Shares (in thousands)		Weighted Average Grant Date Fair Value (per share)
Nonvested, December 31, 2015	2,349		14.87
Granted	948		6.04
Vested	(554	)	15.98
Forfeited	(167	)	15.82
Nonvested, June 30, 2016	2,576		11.40

As of June 30, 2016, there was $21 of unrecognized stock-based compensation expense related to nonvested awards, which is expected to be recognized over a weighted-average period of 1.93 years.

Performance Share Units

During 2016, Chemours issued performance share units (“PSU”) to key senior management employees, which upon vesting, covert one-for-one to Chemours' common stock if specified performance goals, including certain market-based conditions, are met over the three year performance period specified in the grant, subject to exceptions through the respective vesting period of three years. Each grantee is granted a target award of PSUs, and may earn between 0% and 200% of the target amount depending on the Company’s performance against the performance goals. During the three and six months ended June 30, 2016, the Company recorded stock-based compensation related to PSUs as a component of selling, general and administrative expense of approximately less than $1. There were no PSUs granted prior to 2016.

The following table provides compensation costs for stock-based compensation related to PSUs.



	Number of Share Units (in thousands)		Weighted Average Grant Date Fair Value (per share)
Nonvested, December 31, 2015	—		$	—
Granted	825		6.10
Vested	—		—
Forfeited	(22	)	6.10
Nonvested, June 30, 2016	803		$	6.10

A portion of the fair value of PSUs was estimated at the grant date based on the probability of satisfying the market-based conditions associated with the PSUs using the Monte Carlo valuation method, which assesses probabilities of various outcomes of market conditions. The other portion of the fair value of the PSUs is based on the fair market value of the Company’s stock at the grant date, regardless of whether the market-based condition is satisfied. The per unit weighted-average fair value at the date of grant for PSUs granted during the three and six months ended June 30, 2016 was $6.10. The fair value of each PSU grant is amortized monthly into compensation expense on a straight-line basis over their respective vesting periods over 36 months. The accrual of compensation costs is based on our estimate of the final expected value of the award, and is adjusted as required for the portion based on the performance-based condition. The Company assumes that forfeitures will be minimal, and recognizes forfeitures as they occur, which results in a reduction in compensation expense. As the payout of the PSUs includes dividend equivalents, no separate dividend yield assumption is required in calculating the fair value of the PSUs.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Segment Information

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Segment Information

Chemours’ operations are classified into three reportable segments based on similar economic characteristics, the nature of products and production processes, end-use markets, channels of distribution and regulatory environment. Chemours’ reportable segments are Titanium Technologies, Fluoroproducts and Chemical Solutions. Corporate costs and certain legal and environmental expenses that are not aligned with the reportable segments and foreign exchange gains and losses are reflected in Corporate and Other.

Segment sales include transfers to another reportable segment. Certain products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. These product transfers were limited and were not significant for each of the periods presented. Adjusted EBITDA - or Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization, is the primary measure of segment profitability used by the Chief Operating Decision Maker (CODM) and is defined as income (loss) before income taxes excluding the following:


•	interest expense, depreciation and amortization,


•	non-operating pension and other postretirement employee benefit costs, which represent the components of net periodic pension costs (income) excluding service cost component.


•	exchange gains (losses),


•	employee separation, asset-related charges and other charges, net,


•	asset impairments,


•	gains (losses) on sale of business or assets, and


•	other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

The tables presented below reflect the reclassification of certain corporate costs, certain legal and environmental expenses that are not aligned with our reportable segments, and foreign exchange gains and losses from our reportable segments into Corporate and Other. All periods presented reflect the current definition of Adjusted EBITDA.



Three months ended June 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2016
Net sales to external customers	$	596	$	573	$	214	$	—		$	1,383
Adjusted EBITDA	111		105		11		(40		)	187
Depreciation and amortization	32		25		8		8			73

2015
Net sales to external customers	$	642	$	588	$	278	$	—		$	1,508
Adjusted EBITDA	91		54		4		(22		)	127
Depreciation and amortization	32		21		14		—			67



Six months ended June 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2016
Net sales to external customers	$	1,117	$	1,104	$	459	$	—		$	2,680
Adjusted EBITDA	166		190		21		(62		)	315
Depreciation and amortization	54		49		20		16			139

2015
Net sales to external customers	$	1,187	$	1,140	$	544	$	—		$	2,871
Adjusted EBITDA	184		129		5		(46		)	272
Depreciation and amortization	63		42		26		—			131

The following is a tabular reconciliation of consolidated income (loss) before income taxes to Adjusted EBITDA:



	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016			2015
(Loss) income before income taxes	$	(41	)	$	(18	)	$	28		$	40
Interest expense, net	50			28			106			28
Depreciation and amortization	73			67			139			131
Non-operating pension and other postretirement employee benefit (income) costs	(7		)	8			(14		)	15
Exchange losses (gains)	14			(19		)	20			(3		)
Restructuring charges	9			61			27			61
Asset related charges ¹	63			—			63			—
Loss (gain) on sale of assets or business	1			—			(88		)	—
Transaction costs ²	12			—			15			—
Legal and other charges ³	13			—			19			—
Adjusted EBITDA	$	187		$	127		$	315		$	272


¹	Includes the $58 asset impairment in connection with the sale of the Sulfur business (See Note 6) and other asset write-offs in the Chemical Solutions segment.


²	Includes accounting, legal and bankers transaction fees incurred related to the Company's strategic initiatives, which includes pre-sale transaction cost incurred in connection with the sale of the C&D and Sulfur businesses (see Note 6).


³	Includes litigation settlements, water treatment accruals related to PFOA, and lease termination charges.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Guarantor Condensed Consolidating Financial Information

6 Months Ended

Jun. 30, 2016

Condensed Financial Information of Parent Company Only Disclosure [Abstract]

Guarantor Condensed Consolidating Financial Information

In connection with the issuance of the Notes by The Chemours Company (the “Parent Issuer”), this guarantor financial information is included in accordance with Rule 3-10 of Regulation S-X (Rule 3-10). The Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis, in each case, subject to certain exceptions, by the Parent Issuer and by certain subsidiaries (together, the “Guarantor Subsidiaries”). Each of the Guarantor Subsidiaries is 100% owned by the Company. None of the other subsidiaries of the Company, either direct or indirect, guarantee the Notes (together, the “Non-Guarantor Subsidiaries”). The Guarantor Subsidiaries of the Notes, excluding the Parent Issuer, will be automatically released from those guarantees upon the occurrence of certain customary release provisions.

The following condensed consolidating financial information is presented to comply with the Company’s requirements under Rule 3-10:


•	the Consolidating Statements of Comprehensive Income (Loss) for the three and six months ended June 30, 2016 and 2015;


•	the Consolidating Balance Sheets as of June 30, 2016 and December 31, 2015; and


•	the Consolidating Statements of Cash Flows for the six months ended June 30, 2016 and 2015.

As discussed in Note 2, Chemours did not operate as a separate, stand-alone entity for the full period covered by consolidated financial statements. Prior to our separation on July 1, 2015, Chemours operations were included in DuPont’s financial results in different legal forms, including, but not limited to, wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses and a majority owned joint venture. The accompanying condensed consolidated financial information for the three and six months ended June 30, 2015 have been prepared from DuPont’s historical accounting records and are presented on a stand-alone basis as if the business operations had been conducted independently from DuPont.

The condensed consolidating financial information is presented using the equity method of accounting for its investments in 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this footnote should be read in conjunction with the interim consolidated financial statements presented and other notes related thereto contained in this quarterly report.

As discussed in Note 6, the Company entered into a stock and asset purchase agreement with Lanxess, pursuant to which Lanxess has agreed to acquire Chemours’ C&D business by acquiring certain Chemours’ subsidiaries and assets comprising the C&D business, which include a guarantor subsidiary International Dioxcide, Inc. (“IDI”), a restricted subsidiary as defined in the indenture governing the notes. IDI will be automatically released from the guarantees pursuant to the provision of the indenture upon completion of the sale, which is expected in the second half of 2016.

Condensed Consolidating Statements of Comprehensive Income (Loss)



	Three Months Ended June 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	956		$	799		$	(372	)	$	1,383
Cost of goods sold	—			840			648			(372		)	1,116
Gross profit	—			116			151			—			267
Selling, general and administrative expense	5			138			36			(5		)	174
Research and development expense	—			16			1			—			17
Employee separation and asset related charges, net	—			69			(2		)	—			67
Total expenses	5			223			35			(5		)	258
Equity in earnings of affiliates	—			(3		)	7			—			4
Equity in earnings of subsidiaries	5			—			—			(5		)	—
Interest expense, net	(50		)	—			—			—			(50		)
Intercompany interest income (expense), net	14			2			(16		)	—			—
Other income (expense), net	5			9			(17		)	(1		)	(4		)
(Loss) income before income taxes	(31		)	(99		)	90			(1		)	(41		)
(Benefit from) provision for income taxes	(13		)	(33		)	15			8			(23		)
Net (loss) income	(18		)	(66		)	75			(9		)	(18		)
Less: Net income attributable to noncontrolling interests	—			—			—			—			—
Net (loss) income attributable to Chemours	$	(18	)	$	(66	)	$	75		$	(9	)	$	(18	)
Comprehensive (loss) income attributable to Chemours	$	(22	)	$	(66	)	$	67		$	(1	)	$	(22	)

Condensed Consolidating Statements of Comprehensive Income (Loss)



	Three Months Ended June 30, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	1,087		$	871		$	(450	)	$	1,508
Cost of goods sold	—			1,001			729			(448		)	1,282
Gross profit	—			86			142			(2		)	226
Selling, general and administrative expense	—			100			57			—			157
Research and development expense	—			25			2			—			27
Employee separation and asset related charges, net	—			39			22			—			61
Total expenses	—			164			81			—			245
Equity in earnings of affiliates	—			—			8			—			8
Equity in earnings of subsidiaries	(8		)	—			—			8			—
Interest expense, net	(28		)	—			—			—			(28		)
Intercompany interest income (expense), net	12			—			(12		)	—			—
Other income, net	—			20			1			—			21
(Loss) income before income taxes	(24		)	(58		)	58			6			(18		)
(Benefit from) provision for income taxes	(6		)	8			(2		)	—			—
Net (loss) income	(18		)	(66		)	60			6			(18		)
Less: Net income attributable to noncontrolling interests	—			—			—			—			—
Net (loss) income attributable to Chemours	$	(18	)	$	(66	)	$	60		$	6		$	(18	)
Comprehensive (loss) income attributable to Chemours	$	(49	)	$	(66	)	$	29		$	37		$	(49	)

Condensed Consolidating Statements of Comprehensive Income (Loss)



	Six Months Ended June 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	1,937		$	1,520		$	(777	)	$	2,680
Cost of goods sold	—			1,715			1,266			(769		)	2,212
Gross profit	—			222			254			(8		)	468
Selling, general and administrative expense	12			236			69			(10		)	307
Research and development expense	—			38			2			—			40
Employee separation and asset related charges, net	—			87			(2		)	—			85
Total expenses	12			361			69			(10		)	432
Equity in earnings of affiliates	—			(3		)	12			—			9
Equity in earnings of subsidiaries	81			—			—			(81		)	—
Interest expense, net	(105		)	(1		)	—			—			(106		)
Intercompany interest income (expense), net	29			3			(32		)	—			—
Other income (expense), net	10			108			(22		)	(7		)	89
Income (loss) before income taxes	3			(32		)	143			(86		)	28
(Benefit from) provision for income taxes	(30		)	(4		)	24			5			(5		)
Net income (loss)	33			(28		)	119			(91		)	33
Less: Net income attributable to noncontrolling interests	—			—			—			—			—
Net income (loss) attributable to Chemours	$	33		$	(28	)	$	119		$	(91	)	$	33
Comprehensive income (loss) attributable to Chemours	$	40		$	(28	)	$	129		$	(101	)	$	40

Condensed Consolidating Statements of Comprehensive Income (Loss)



	Six Months Ended June 30, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	2,114		$	1,632		$	(875	)	$	2,871
Cost of goods sold	—			1,893			1,382			(882		)	2,393
Gross profit	—			221			250			7			478
Selling, general and administrative expense	—			209			115			—			324
Research and development expense	—			48			2			—			50
Employee separation and asset related charges, net	—			39			22			—			61
Total expenses	—			296			139			—			435
Equity in earnings of affiliates	—			—			11			—			11
Equity in earnings of subsidiaries	35			—			—			(35		)	—
Interest expense, net	(28		)	—			—			—			(28		)
Intercompany interest income (expense), net	12			—			(12		)	—			—
Other income (expense), net	—			18			(4		)	—			14
Income (loss) before income taxes	19			(57		)	106			(28		)	40
(Benefit from) provision for income taxes	(6		)	8			13			—			15
Net income (loss)	25			(65		)	93			(28		)	25
Less: Net income attributable to noncontrolling interests	—			—			—			—			—
Net income (loss) attributable to Chemours	$	25		$	(65	)	$	93		$	(28	)	$	25
Comprehensive loss attributable to Chemours	$	(182	)	$	(65	)	$	(114	)	$	179		$	(182	)

Condensed Consolidating Balance Sheets



	June 30, 2016
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash	$	—	$	71		$	312		$	—		$	383
Accounts and notes receivable - trade, net	—		422			517			—			939
Intercompany receivable	2		677			64			(743		)	—
Inventories	—		413			507			(28		)	892
Prepaid expenses and other	—		17			50			(15		)	52
Assets held-for-sale	—		20			6			—			26
Total current assets	2		1,620			1,456			(786		)	2,292
Property, plant and equipment	—		6,394			1,940			—			8,334
Less: Accumulated depreciation	—		(4,491		)	(953		)	—			(5,444		)
Net property, plant and equipment	—		1,903			987			—			2,890
Goodwill	—		139			14			—			153
Other intangible assets, net	—		8			—			—			8
Investments in affiliates	—		6			151			—			157
Investment in subsidiaries	3,250		—			—			(3,250		)	—
Intercompany notes receivable	1,150		—			—			(1,150		)	—
Assets held-for-sale	—		339			13			—			352
Other assets	15		119			235			—			369
Total assets	$	4,417	$	4,134		$	2,856		$	(5,186	)	$	6,221
Liabilities and equity
Current liabilities:
Accounts payable	$	—	$	575		$	300		$	—		$	875
Short-term borrowings and current maturities of long-term debt	15		21			—			—			36
Intercompany payable	393		64			286			(743		)	—
Other accrued liabilities	23		395			115			—			533
Total current liabilities	431		1,055			701			(743		)	1,444
Long-term debt	3,821		2			—			—			3,823
Intercompany notes payable	—		—			1,150			(1,150		)	—
Deferred income taxes	—		134			51			17			202
Other liabilities	—		479			104			—			583
Total liabilities	4,252		1,670			2,006			(1,876		)	6,052
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	165		2,464			846			(3,310		)	165
Noncontrolling interests	—		—			4			—			4
Total equity	165		2,464			850			(3,310		)	169
Total liabilities and equity	$	4,417	$	4,134		$	2,856		$	(5,186	)	$	6,221

Condensed Consolidating Balance Sheets



	December 31, 2015
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash	$	—	$	95		$	271		$	—		$	366
Accounts and notes receivable - trade, net	—		344			515			—			859
Intercompany receivable	3		459			54			(516		)	—
Inventories	—		493			501			(22		)	972
Prepaid expenses and other	—		3			52			3			58
Assets held-for-sale	—		46			—			—			46
Total current assets	3		1,440			1,393			(535		)	2,301
Property, plant and equipment	—		7,070			1,945			—			9,015
Less: Accumulated depreciation	—		(4,899		)	(939		)	—			(5,838		)
Net property, plant and equipment	—		2,171			1,006			—			3,177
Goodwill	—		141			25			—			166
Other intangible assets, net	—		10			—			—			10
Investments in affiliates	—		9			127			—			136
Investments in subsidiaries	3,105		—			—			(3,105		)	—
Intercompany notes receivable	1,150		—			—			(1,150		)	—
Other assets	19		275			214			—			508
Total assets	$	4,277	$	4,046		$	2,765		$	(4,790	)	$	6,298
Liabilities and equity
Current liabilities:
Accounts payable	$	—	$	637		$	336		$	—		$	973
Short-term borrowings and current maturities of long-term debt	15		24			—			—			39
Intercompany payable	202		54			260			(516		)	—
Other accrued liabilities	21		287			146			—			454
Total current liabilities	238		1,002			742			(516		)	1,466
Long-term debt	3,913		2			—			—			3,915
Intercompany notes payable	—		—			1,150			(1,150		)	—
Deferred income taxes	—		173			61			—			234
Other liabilities	—		456			97			—			553
Total liabilities	4,151		1,633			2,050			(1,666		)	6,168
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	126		2,413			711			(3,124		)	126
Noncontrolling interests	—		—			4			—			4
Total equity	126		2,413			715			(3,124		)	130
Total liabilities and equity	$	4,277	$	4,046		$	2,765		$	(4,790	)	$	6,298

Condensed Consolidating Statements of Cash Flows



	Six Months Ended June 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash (used for) provided by operating activities	$	(86	)	$	(48	)	$	97		$	163		$	126
Investing activities
Purchases of property, plant and equipment	—			(95		)	(73		)	—			(168		)
Proceeds from sales of assets and business	—			150			—			—			150
Intercompany investing activities	—			(28		)	—			28			—
Cash provided by (used for) investing activities	—			27			(73		)	28			(18		)
Financing activities
Intercompany short-term borrowings, net	191			—			—			(191		)	—
Debt repayments	(92		)	(3		)	—			—			(95		)
Dividends paid	(11		)	—			—			—			(11		)
Deferred financing fees	(2		)	—			—			—			(2		)
Cash provided by (used for) financing activities	86			(3		)	—			(191		)	(108		)
Effect of exchange rate changes on cash	—			—			17			—			17
Increase in cash	—			(24		)	41			—			17
Cash at beginning of period	—			95			271			—			366
Cash at end of period	$	—		$	71		$	312		$	—		$	383



	Six Months Ended June 30, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash provided by (used for) operating activities	$	5		$	206		$	(245	)	$	(199	)	$	(233	)
Investing activities
Purchases of property, plant and equipment	—			(173		)	(114		)	—			(287		)
Proceeds from sales of assets and business	—			6			2			—			8
Foreign exchange contract settlements	—			(12		)	—			—			(12		)
Investment in affiliates	—			—			(32		)	—			(32		)
Cash used for investing activities	—			(179		)	(144		)	—			(323		)
Financing activities
Proceeds from issuance of debt, net	3,489			1			—			—			3,490
Deferred financing fees	(77		)	—			—			—			(77		)
Cash provided at separation by DuPont	—			87			160			—			247
Net transfers (to) from DuPont	(3,417		)	(28		)	389			199			(2,857		)
Cash (used for) provided by financing activities	(5		)	60			549			199			803
Effect of exchange rate changes on cash	—			—			—			—			—
Increase in cash	—			87			160			—			247
Cash at beginning of period	—			—			—			—			—
Cash at end of period	$	—		$	87		$	160		$	—		$	247

Recent Accounting Pronouncements (Policies)	6 Months Ended
Recent Accounting Pronouncements (Policies)	Jun. 30, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	In March through May 2016, the Financial Accounting Standards Board (FASB) issued various updates to the Accounting Standards Update (ASU) No. 2014-09, “Revenue from contracts with customers (Topic 606).” The additional updates provide further clarifications on certain objectives and application of the core principle of Topic 606 for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The guidance is effective for public entities for annual and interim periods beginning after December 15, 2016 (original effective date), with one year deferral permitted from the original effective date. Chemours is currently evaluating the impact of adopting the guidance on its financial positions and results of operations and expects to adopt the guidance effective January 1, 2018. In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718).” The update sets forth areas for simplification within several aspects of the accounting for shared-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this update are effective for fiscal periods, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted for any entity in any interim or annual period. Chemours is currently evaluating the impact of adopting this guidance but does not expect the adoption will have a significant impact on its financial position or results of operations. Also, in March 2016, the FASB issued ASU 2016-07, “Investments—Equity Method and Joint Ventures (Topic 323).” The amendments eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments should be applied prospectively upon their effective date to increases in the level of ownership interest or degree of influence that result in the adoption of the equity method. Earlier application is permitted. Adoption of this guidance is not expected to have a significant impact on the Company's financial position or results of operations. Further, in March 2016, the FASB issued ASU 2016-06, “Derivatives and Hedging (Topic 815), Contingent Put and Call Options in Debt Instruments,” which clarifies Topic 815 requirements for assessing whether contingent call and/or put options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under the amendments in this update is required to assess the embedded call and/or put options solely in accordance with the four-step decision sequence. The amendments in this update are effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years, and the entity should apply the amendments on a modified retrospective basis to existing debt instruments as of the beginning of the fiscal year for which the amendments are effective. Adoption of this guidance is not expected to have a significant impact on the Company's financial position or results of operations. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which supersedes the leases requirements in Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases in accordance with FASB Concepts Statement No. 6, Elements of Financial Statements, and, therefore, recognition of those lease assets and lease liabilities represents an improvement over previous GAAP, which did not require lease assets and lease liabilities to be recognized for most leases. A qualitative disclosure along with specific quantitative disclosures is required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities. Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients that entities may elect to apply. The amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application of the amendments in this update is permitted for all entities. Chemours is currently evaluating the impact of adopting this guidance on its financial position, results of operations and debt covenants. In May 2015, the FASB issued ASU No. 2015-07, “Fair Value Measurement (Topic 820) - Disclosures for Investment in Certain Entities that Calculate Net Asset Value per Share or its Equivalent.” This guidance removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The guidance also removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The amendment is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. A reporting entity should apply the amendments retrospectively to all periods presented and earlier application is permitted. Chemours adopted this guidance effective January 1, 2016. The adoption did not have a significant effect on our financial position or results of operations. In April 2015, the FASB issued ASU 2015-05, “Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement,” which provides guidance about whether a cloud computing arrangement includes a software license. The customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. Chemours adopted this guidance effective January 1, 2016 prospectively to all arrangements entered into or materially modified after the effective date. The adoption did not have a significant impact on our financial position or results of operations. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis.” The amendments modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities and eliminate the presumption that a general partner should consolidate a limited partnership. The amendment is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Chemours adopted this guidance effective January 1, 2016 and the adoption did not change our consolidated entities, and therefore had no effect on our financial position, results of operations and cash flows. In June 2014, the FASB issued ASU No. 2014-12, “Compensation-Stock Compensation (Topic 718),” which requires an entity to treat a performance target that affects vesting and that could be achieved after the requisite service period as a performance condition in accordance with existing guidance in Topic 718. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Chemours adopted this guidance, effective January 1, 2016, prospectively to all awards granted or modified after the effective date. The adoption did not have a significant effect on our financial position or results of operations.

Employee Separation and Asset Related Charges, Net (Tables)

6 Months Ended

Jun. 30, 2016

Restructuring Charges [Abstract]

Schedule of Restructuring Program

For the three and six months ended June 30, 2016 and 2015, Chemours recorded charges for employee separation and other restructuring related charges as follows:



	Three months ended June 30,					Six months ended June 30,
	2016			2015		2016		2015
Employee separation (credit) charges	$	(2	)	$	61	$	2	$	61
Decommissioning and other charges	11			—		25		—
Asset related charges - Impairment ¹	58			—		58		—
Total	$	67		$	61	$	85	$	61


¹	Represents an asset impairment in connection with the sale of the Sulfur business. See Note 6 for further information.

Schedule of Restructuring Charges

The restructuring program charges impacted segment earnings for the three and six months ended June 30, 2016 and 2015 as follows:



	Three months ended June 30,					Six months ended June 30,
	2016			2015		2016		2015
Plant and product line closures
Titanium Technologies	$	9		$	—	$	18	$	—
Fluoroproducts	1			—		5		—
Chemical Solutions	(1		)	—		—		—
Total	$	9		$	—	$	23	$	—

2015 Global restructuring ¹
Titanium Technologies	$	—		$	23	$	2	$	23
Fluoroproducts	—			25		2		25
Chemical Solutions	—			13		—		13
Total	$	—		$	61	$	4	$	61

¹ Includes approximately $13 related to Corporate overhead functions that was allocated to our segments for the three and six months ended June 30, 2015.

The following table shows the change in the employee separation related liability account associated with the restructuring programs:



	Titanium Technologies Site Closures			Fluoroproducts Lines Shutdown			Chemical Solutions Site Closures			2015 Global Restructuring			Total
Balance as of December 31, 2015	$	11		$	2		$	12		$	73		$	98
Charges (credits) to income for the six months ended June 30, 2016 ¹	—			—			(2		)	4			2
Charges to liability accounts:
Payments	(4		)	(1		)	—			(36		)	(41		)
Net currency translation and other adjustment ²	—			—			—			—			—
Balance as of June 30, 2016	$	7		$	1		$	10		$	41		$	59


¹	Due to unexpected resignations of certain employees at the Company's Niagara site, approximately $2 of employee separation charges, related to the Chemical Solutions Niagara site closure action announced in the fourth quarter of 2015, were reversed to income in the three and six months ended June 30, 2016.


²	Net currency translation adjustment was less than $1 for the period presented.

Sales of Assets and Businesses (Tables)

6 Months Ended

Jun. 30, 2016

Discontinued Operations and Disposal Groups [Abstract]

Major Components of Assets Held for Sale

The major components of assets held-for-sale are as follows:



	June 30, 2016			December 31, 2015
Current assets:
Accounts receivables	$	21		$	—
Inventories	5			5
Total current assets	26			5
Property, plant and equipment, net	260			30
Goodwill	13			4
Other assets	137			7
Less: Impairment loss	(58		)	—
Total non-current assets, net	352			41
Total assets held-for-sale, net	$	378		$	46

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Other Income (Expense), Net (Tables)

6 Months Ended

Jun. 30, 2016

Other Income and Expenses [Abstract]

Schedule of Other Income (Expense)



	Three months ended June 30,					Six months ended June 30,
	2016			2015		2016			2015
Leasing, contract services and miscellaneous income ¹	$	5		$	—	$	12		$	4
Royalty income²	6			2		9			7
(Loss) gain on sale of assets and business ³	(1		)	—		88			—
Exchange (losses) gains, net ⁴	(14		)	19		(20		)	3
Total other (expense) income, net	$	(4	)	$	21	$	89		$	14

¹Miscellaneous income includes accrued interest related to unrecognized tax benefits.

²Royalty income is primarily for technology and trademark licensing.

³The six months ended June 30, 2016 includes gain on sale of the aniline facility in Beaumont, TX. See Note 6 for additional information.

⁴Exchange losses, net includes gains and loss on foreign currency forward contracts. See Note 17 for additional information

Earnings Per Share of Common Stock (Tables)

6 Months Ended

Jun. 30, 2016

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The table below shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated:



	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016		2015
Numerator:
Net (loss) income attributable to Chemours	$	(18	)	$	(18	)	$	33	$	25
Denominator:
Weighted-average number of common shares outstanding - Basic ¹	181,477,672			180,966,833			181,379,419		180,966,833
Dilutive effect of the company's employee compensation plans²	—			—			668,410		—
Weighted average number of common shares outstanding - Diluted ²	181,477,672			180,966,833			182,047,829		180,966,833

¹For June 30, 2015, pro forma earnings per share was calculated based on 180,966,833 shares of Chemours common stock that were distributed to DuPont shareholders on July 1, 2015.

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following average number of stock options were antidilutive and, therefore, were not included in the diluted earnings per share calculation:



	Three months ended June 30,		Six months ended June 30,
	2016	2015	2016	2015
Average number of stock options	7,356,050	—	8,028,762	—

Accounts and Notes Receivable - Trade, Net (Tables)

6 Months Ended

Jun. 30, 2016

Receivables [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable



	June 30, 2016		December 31, 2015
Accounts receivable—trade, net ¹	$	849	$	759
VAT, GST and other taxes ²	74		68
Leases receivable—current ³	—		13
Other receivables ⁴	16		19
Total	$	939	$	859


¹	Accounts receivable – trade, net includes trade notes receivable and is net of allowances of $4 and $4 as of June 30, 2016 and December 31, 2015, respectively. Allowances are equal to the estimated uncollectible amounts.


²	Value Added Tax (VAT) and Goods and Services Tax (GST).


³	See Note 14 for information relating to direct financing leases.


⁴	Other receivables consist of advances and other deposits

Inventories (Tables)

6 Months Ended

Jun. 30, 2016

Inventory, Net [Abstract]

Schedule of Inventories



	June 30, 2016			December 31, 2015
Finished products	$	628		$	613
Semi-finished products	169			172
Raw materials, stores and supplies	332			433
Subtotal	1,129			1,218
Adjustment of inventories to a last-in, first-out (LIFO) basis	(237		)	(246		)
Total	$	892		$	972

Goodwill and Other Intangible Assets, Net (Tables)

6 Months Ended

Jun. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The following table summarizes changes in the carrying amount of goodwill by reportable segment:



	Titanium Technologies		Fluoroproducts		Chemical Solutions			Total
Balance as of December 31, 2015	$	13	$	85	$	68		$	166
Asset held-for-sale ¹	—		—		(13		)	(13		)
Currency translation adjustment ²	—		—		—			—
Balance as of June 30, 2016	$	13	$	85	$	55		$	153


¹	Represents the reclassification of goodwill to assets held-for-sale in connection with the sale of the C&D business (See Note 6).


²	Net currency translation adjustment was less than $1 for the period presented.

Schedule of Intangible Assets

The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class:



	June 30, 2016							December 31, 2015
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer lists	$	12	$	(10	)	$	2	$	13	$	(10	)	$	3
Patents	19		(17		)	2		19		(17		)	2
Purchased trademarks	5		(2		)	3		5		(2		)	3
Purchased and licensed technology	3		(2		)	1		8		(6		)	2
Total	$	39	$	(31	)	$	8	$	45	$	(35	)	$	10

Summary of Estimated Amortization Expense

The estimated amortization for the remainder of 2016 and each of the succeeding four years is:



Remainder of 2016	$	1
2017	2
2018	1
2019	1
2020	1

Other Assets (Tables)

6 Months Ended

Jun. 30, 2016

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Assets



	June 30, 2016		December 31, 2015
Leases receivable - non-current ¹	$	—	$	125
Capitalized repair and maintenance costs	111		149
Pension assets ²	164		138
Deferred income taxes - non-current	46		47
Miscellaneous ³	48		49
Total	$	369	$	508


¹	Relates to Sulfur business which was reclassified to assets held-for-sale as of June 30, 2016. See Direct Financing Leases below.

²Pension assets represent the funded status of certain of the Company's long-term employee benefit plans.

³Miscellaneous includes deferred financing fees related to the Revolving Credit Facility of $15 and $19 as of June 30, 2016 and December 31, 2015, respectively.

Debt (Tables)

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

Long-term debt was comprised of the following at June 30, 2016 and December 31, 2015:



	June 30, 2016		December 31, 2015
Long-term debt:
Senior secured term loan	$	1,435	$	1,493
Senior unsecured notes:
6.625%, due May 2023	1,308		1,350
7.00%, due May 2025	750		750
6.125%, due May 2023 (€360)	398		395
Other	23		26
Total	3,914		4,014
Less: Unamortized issue discount on senior secured term loan	6		7
Less: Unamortized debt issuance costs	49		53
Less: Current maturities	36		39
Total long-term debt	$	3,823	$	3,915

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Commitments and Contingent Liabilities (Tables)

6 Months Ended

Jun. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Summary of Plaintiffs in Case

Although the majority of the plaintiffs in the MDL allege multiple diseases, the table below approximates the number of plaintiffs in each of the six probable link disease categories.



Alleged Injury	Approximate Number of Plaintiffs
Kidney cancer	200
Testicular cancer	70
Ulcerative colitis	300
Preeclampsia	200
Thyroid disease	1,430
High cholesterol	1,340

- Definition

Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349

+ Details

Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Assets at Fair Value

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy:



		Fair Value Using Level 2 Inputs
	Balance Sheet Location	June 30, 2016		December 31, 2015
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	2	$	2
Total asset derivatives		$	2	$	2

Liability derivatives
Foreign currency forward contracts	Other accrued liabilities	$	2	$	2
Total liability derivatives		$	2	$	2

Schedule of Derivative Liabilities at Fair Value

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy:



		Fair Value Using Level 2 Inputs
	Balance Sheet Location	June 30, 2016		December 31, 2015
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	2	$	2
Total asset derivatives		$	2	$	2

Liability derivatives
Foreign currency forward contracts	Other accrued liabilities	$	2	$	2
Total liability derivatives		$	2	$	2

Long-Term Employee Benefits (Tables)

6 Months Ended

Jun. 30, 2016

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Schedules of Net Periodic Benefit Cost (Income)

The components of net periodic benefit (income) cost for all significant pension plans were as follows:



	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016			2015
Service cost	$	4		$	3		$	7		$	6
Interest cost	5			4			10			9
Expected return on plan assets	(17		)	(20		)	(33		)	(41		)
Amortization of actuarial net loss	7			3			11			7
Amortization of prior service cost (gain)	—			1			(1		)	2
Curtailment gain	(2		)	—			(2		)	—
Net periodic benefit income	$	(3	)	$	(9	)	$	(8	)	$	(17	)

Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock Options Valuation Assumptions

The expense related to stock options granted in the six months ended June 30, 2016 was based on the weighted-average assumptions shown in the table below. No stock options were granted by Chemours in the three and six months ended June 30, 2015.



Weighted-Average Assumptions	June 30, 2016
Risk-free interest rate	1.46		%
Expected term (years)	6.00
Volatility	80.90		%
Dividend yield	2.14		%
Fair value per stock option	$	3.41

Schedule of Stock Options Activity

The following table summarizes Chemours stock option activity for the six months ended June 30, 2016.



	Number of Shares (in thousands)		Weighted Average Exercise Price (per share)		Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2015	8,284		$	14.66	4.82	$	—
Granted	1,406		5.73
Exercised	(12	)	8.38
Forfeited	(252	)	15.46
Expired	(356	)	5.82
Outstanding, June 30, 2016	9,070		13.60		5.28	$	3,556
Exercisable, June 30, 2016	4,928		13.69		3.55	$	—

Schedule of Restricted Stock Units Activity

Non-vested awards of RSUs, both with and without a performance condition, as of June 30, 2016 are shown below.



	Number of Shares (in thousands)		Weighted Average Grant Date Fair Value (per share)
Nonvested, December 31, 2015	2,349		14.87
Granted	948		6.04
Vested	(554	)	15.98
Forfeited	(167	)	15.82
Nonvested, June 30, 2016	2,576		11.40

Schedule of Performance Share Units Activity

The following table provides compensation costs for stock-based compensation related to PSUs.



	Number of Share Units (in thousands)		Weighted Average Grant Date Fair Value (per share)
Nonvested, December 31, 2015	—		$	—
Granted	825		6.10
Vested	—		—
Forfeited	(22	)	6.10
Nonvested, June 30, 2016	803		$	6.10

Segment Information (Tables)

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Schedule of Segment Information



Three months ended June 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2016
Net sales to external customers	$	596	$	573	$	214	$	—		$	1,383
Adjusted EBITDA	111		105		11		(40		)	187
Depreciation and amortization	32		25		8		8			73

2015
Net sales to external customers	$	642	$	588	$	278	$	—		$	1,508
Adjusted EBITDA	91		54		4		(22		)	127
Depreciation and amortization	32		21		14		—			67



Six months ended June 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2016
Net sales to external customers	$	1,117	$	1,104	$	459	$	—		$	2,680
Adjusted EBITDA	166		190		21		(62		)	315
Depreciation and amortization	54		49		20		16			139

2015
Net sales to external customers	$	1,187	$	1,140	$	544	$	—		$	2,871
Adjusted EBITDA	184		129		5		(46		)	272
Depreciation and amortization	63		42		26		—			131

Reconciliation of EBITDA from Segments to Consolidated

The following is a tabular reconciliation of consolidated income (loss) before income taxes to Adjusted EBITDA:



	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016			2015
(Loss) income before income taxes	$	(41	)	$	(18	)	$	28		$	40
Interest expense, net	50			28			106			28
Depreciation and amortization	73			67			139			131
Non-operating pension and other postretirement employee benefit (income) costs	(7		)	8			(14		)	15
Exchange losses (gains)	14			(19		)	20			(3		)
Restructuring charges	9			61			27			61
Asset related charges ¹	63			—			63			—
Loss (gain) on sale of assets or business	1			—			(88		)	—
Transaction costs ²	12			—			15			—
Legal and other charges ³	13			—			19			—
Adjusted EBITDA	$	187		$	127		$	315		$	272


¹	Includes the $58 asset impairment in connection with the sale of the Sulfur business (See Note 6) and other asset write-offs in the Chemical Solutions segment.


²	Includes accounting, legal and bankers transaction fees incurred related to the Company's strategic initiatives, which includes pre-sale transaction cost incurred in connection with the sale of the C&D and Sulfur businesses (see Note 6).


³	Includes litigation settlements, water treatment accruals related to PFOA, and lease termination charges.

Guarantor Condensed Consolidating Financial Information (Tables)

6 Months Ended

Jun. 30, 2016

Condensed Financial Information of Parent Company Only Disclosure [Abstract]

Condensed Consolidating Statements of Comprehensive (Loss) Income

Condensed Consolidating Statements of Comprehensive Income (Loss)



	Three Months Ended June 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	956		$	799		$	(372	)	$	1,383
Cost of goods sold	—			840			648			(372		)	1,116
Gross profit	—			116			151			—			267
Selling, general and administrative expense	5			138			36			(5		)	174
Research and development expense	—			16			1			—			17
Employee separation and asset related charges, net	—			69			(2		)	—			67
Total expenses	5			223			35			(5		)	258
Equity in earnings of affiliates	—			(3		)	7			—			4
Equity in earnings of subsidiaries	5			—			—			(5		)	—
Interest expense, net	(50		)	—			—			—			(50		)
Intercompany interest income (expense), net	14			2			(16		)	—			—
Other income (expense), net	5			9			(17		)	(1		)	(4		)
(Loss) income before income taxes	(31		)	(99		)	90			(1		)	(41		)
(Benefit from) provision for income taxes	(13		)	(33		)	15			8			(23		)
Net (loss) income	(18		)	(66		)	75			(9		)	(18		)
Less: Net income attributable to noncontrolling interests	—			—			—			—			—
Net (loss) income attributable to Chemours	$	(18	)	$	(66	)	$	75		$	(9	)	$	(18	)
Comprehensive (loss) income attributable to Chemours	$	(22	)	$	(66	)	$	67		$	(1	)	$	(22	)

Condensed Consolidating Statements of Comprehensive Income (Loss)



	Three Months Ended June 30, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	1,087		$	871		$	(450	)	$	1,508
Cost of goods sold	—			1,001			729			(448		)	1,282
Gross profit	—			86			142			(2		)	226
Selling, general and administrative expense	—			100			57			—			157
Research and development expense	—			25			2			—			27
Employee separation and asset related charges, net	—			39			22			—			61
Total expenses	—			164			81			—			245
Equity in earnings of affiliates	—			—			8			—			8
Equity in earnings of subsidiaries	(8		)	—			—			8			—
Interest expense, net	(28		)	—			—			—			(28		)
Intercompany interest income (expense), net	12			—			(12		)	—			—
Other income, net	—			20			1			—			21
(Loss) income before income taxes	(24		)	(58		)	58			6			(18		)
(Benefit from) provision for income taxes	(6		)	8			(2		)	—			—
Net (loss) income	(18		)	(66		)	60			6			(18		)
Less: Net income attributable to noncontrolling interests	—			—			—			—			—
Net (loss) income attributable to Chemours	$	(18	)	$	(66	)	$	60		$	6		$	(18	)
Comprehensive (loss) income attributable to Chemours	$	(49	)	$	(66	)	$	29		$	37		$	(49	)

Condensed Consolidating Statements of Comprehensive Income (Loss)



	Six Months Ended June 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	1,937		$	1,520		$	(777	)	$	2,680
Cost of goods sold	—			1,715			1,266			(769		)	2,212
Gross profit	—			222			254			(8		)	468
Selling, general and administrative expense	12			236			69			(10		)	307
Research and development expense	—			38			2			—			40
Employee separation and asset related charges, net	—			87			(2		)	—			85
Total expenses	12			361			69			(10		)	432
Equity in earnings of affiliates	—			(3		)	12			—			9
Equity in earnings of subsidiaries	81			—			—			(81		)	—
Interest expense, net	(105		)	(1		)	—			—			(106		)
Intercompany interest income (expense), net	29			3			(32		)	—			—
Other income (expense), net	10			108			(22		)	(7		)	89
Income (loss) before income taxes	3			(32		)	143			(86		)	28
(Benefit from) provision for income taxes	(30		)	(4		)	24			5			(5		)
Net income (loss)	33			(28		)	119			(91		)	33
Less: Net income attributable to noncontrolling interests	—			—			—			—			—
Net income (loss) attributable to Chemours	$	33		$	(28	)	$	119		$	(91	)	$	33
Comprehensive income (loss) attributable to Chemours	$	40		$	(28	)	$	129		$	(101	)	$	40

Condensed Consolidating Statements of Comprehensive Income (Loss)



	Six Months Ended June 30, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	2,114		$	1,632		$	(875	)	$	2,871
Cost of goods sold	—			1,893			1,382			(882		)	2,393
Gross profit	—			221			250			7			478
Selling, general and administrative expense	—			209			115			—			324
Research and development expense	—			48			2			—			50
Employee separation and asset related charges, net	—			39			22			—			61
Total expenses	—			296			139			—			435
Equity in earnings of affiliates	—			—			11			—			11
Equity in earnings of subsidiaries	35			—			—			(35		)	—
Interest expense, net	(28		)	—			—			—			(28		)
Intercompany interest income (expense), net	12			—			(12		)	—			—
Other income (expense), net	—			18			(4		)	—			14
Income (loss) before income taxes	19			(57		)	106			(28		)	40
(Benefit from) provision for income taxes	(6		)	8			13			—			15
Net income (loss)	25			(65		)	93			(28		)	25
Less: Net income attributable to noncontrolling interests	—			—			—			—			—
Net income (loss) attributable to Chemours	$	25		$	(65	)	$	93		$	(28	)	$	25
Comprehensive loss attributable to Chemours	$	(182	)	$	(65	)	$	(114	)	$	179		$	(182	)

Condensed Consolidating Balance Sheets



	June 30, 2016
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash	$	—	$	71		$	312		$	—		$	383
Accounts and notes receivable - trade, net	—		422			517			—			939
Intercompany receivable	2		677			64			(743		)	—
Inventories	—		413			507			(28		)	892
Prepaid expenses and other	—		17			50			(15		)	52
Assets held-for-sale	—		20			6			—			26
Total current assets	2		1,620			1,456			(786		)	2,292
Property, plant and equipment	—		6,394			1,940			—			8,334
Less: Accumulated depreciation	—		(4,491		)	(953		)	—			(5,444		)
Net property, plant and equipment	—		1,903			987			—			2,890
Goodwill	—		139			14			—			153
Other intangible assets, net	—		8			—			—			8
Investments in affiliates	—		6			151			—			157
Investment in subsidiaries	3,250		—			—			(3,250		)	—
Intercompany notes receivable	1,150		—			—			(1,150		)	—
Assets held-for-sale	—		339			13			—			352
Other assets	15		119			235			—			369
Total assets	$	4,417	$	4,134		$	2,856		$	(5,186	)	$	6,221
Liabilities and equity
Current liabilities:
Accounts payable	$	—	$	575		$	300		$	—		$	875
Short-term borrowings and current maturities of long-term debt	15		21			—			—			36
Intercompany payable	393		64			286			(743		)	—
Other accrued liabilities	23		395			115			—			533
Total current liabilities	431		1,055			701			(743		)	1,444
Long-term debt	3,821		2			—			—			3,823
Intercompany notes payable	—		—			1,150			(1,150		)	—
Deferred income taxes	—		134			51			17			202
Other liabilities	—		479			104			—			583
Total liabilities	4,252		1,670			2,006			(1,876		)	6,052
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	165		2,464			846			(3,310		)	165
Noncontrolling interests	—		—			4			—			4
Total equity	165		2,464			850			(3,310		)	169
Total liabilities and equity	$	4,417	$	4,134		$	2,856		$	(5,186	)	$	6,221

Condensed Consolidating Balance Sheets



	December 31, 2015
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash	$	—	$	95		$	271		$	—		$	366
Accounts and notes receivable - trade, net	—		344			515			—			859
Intercompany receivable	3		459			54			(516		)	—
Inventories	—		493			501			(22		)	972
Prepaid expenses and other	—		3			52			3			58
Assets held-for-sale	—		46			—			—			46
Total current assets	3		1,440			1,393			(535		)	2,301
Property, plant and equipment	—		7,070			1,945			—			9,015
Less: Accumulated depreciation	—		(4,899		)	(939		)	—			(5,838		)
Net property, plant and equipment	—		2,171			1,006			—			3,177
Goodwill	—		141			25			—			166
Other intangible assets, net	—		10			—			—			10
Investments in affiliates	—		9			127			—			136
Investments in subsidiaries	3,105		—			—			(3,105		)	—
Intercompany notes receivable	1,150		—			—			(1,150		)	—
Other assets	19		275			214			—			508
Total assets	$	4,277	$	4,046		$	2,765		$	(4,790	)	$	6,298
Liabilities and equity
Current liabilities:
Accounts payable	$	—	$	637		$	336		$	—		$	973
Short-term borrowings and current maturities of long-term debt	15		24			—			—			39
Intercompany payable	202		54			260			(516		)	—
Other accrued liabilities	21		287			146			—			454
Total current liabilities	238		1,002			742			(516		)	1,466
Long-term debt	3,913		2			—			—			3,915
Intercompany notes payable	—		—			1,150			(1,150		)	—
Deferred income taxes	—		173			61			—			234
Other liabilities	—		456			97			—			553
Total liabilities	4,151		1,633			2,050			(1,666		)	6,168
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	126		2,413			711			(3,124		)	126
Noncontrolling interests	—		—			4			—			4
Total equity	126		2,413			715			(3,124		)	130
Total liabilities and equity	$	4,277	$	4,046		$	2,765		$	(4,790	)	$	6,298

Condensed Consolidating Statements of Cash Flows



	Six Months Ended June 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash (used for) provided by operating activities	$	(86	)	$	(48	)	$	97		$	163		$	126
Investing activities
Purchases of property, plant and equipment	—			(95		)	(73		)	—			(168		)
Proceeds from sales of assets and business	—			150			—			—			150
Intercompany investing activities	—			(28		)	—			28			—
Cash provided by (used for) investing activities	—			27			(73		)	28			(18		)
Financing activities
Intercompany short-term borrowings, net	191			—			—			(191		)	—
Debt repayments	(92		)	(3		)	—			—			(95		)
Dividends paid	(11		)	—			—			—			(11		)
Deferred financing fees	(2		)	—			—			—			(2		)
Cash provided by (used for) financing activities	86			(3		)	—			(191		)	(108		)
Effect of exchange rate changes on cash	—			—			17			—			17
Increase in cash	—			(24		)	41			—			17
Cash at beginning of period	—			95			271			—			366
Cash at end of period	$	—		$	71		$	312		$	—		$	383



	Six Months Ended June 30, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash provided by (used for) operating activities	$	5		$	206		$	(245	)	$	(199	)	$	(233	)
Investing activities
Purchases of property, plant and equipment	—			(173		)	(114		)	—			(287		)
Proceeds from sales of assets and business	—			6			2			—			8
Foreign exchange contract settlements	—			(12		)	—			—			(12		)
Investment in affiliates	—			—			(32		)	—			(32		)
Cash used for investing activities	—			(179		)	(144		)	—			(323		)
Financing activities
Proceeds from issuance of debt, net	3,489			1			—			—			3,490
Deferred financing fees	(77		)	—			—			—			(77		)
Cash provided at separation by DuPont	—			87			160			—			247
Net transfers (to) from DuPont	(3,417		)	(28		)	389			199			(2,857		)
Cash (used for) provided by financing activities	(5		)	60			549			199			803
Effect of exchange rate changes on cash	—			—			—			—			—
Increase in cash	—			87			160			—			247
Cash at beginning of period	—			—			—			—			—
Cash at end of period	$	—		$	87		$	160		$	—		$	247

Background and Description of the Business - Narrative (Details)		6 Months Ended
	Jul. 01, 2015	Jun. 30, 2016 facility segment $ / shares	Jun. 23, 2015 $ / shares
Segment Reporting Information [Line Items]
Number of reportable segments \| segment		3
Number of facilities		34
Common stock , par value (USD per share) \| $ / shares		$ 0.01	$ 0.01
Spin off transaction distribution ratio	0.2
Parent Company [Member]
Segment Reporting Information [Line Items]
Common stock , par value (USD per share) \| $ / shares			$ 0.30
Operating Segments [Member]
Segment Reporting Information [Line Items]
Number of facilities		1
Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Number of facilities		5
Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Number of facilities		16
Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Number of facilities		12
Clean & Disinfect and Sulfur Businesses [Member] \| Assets Held-for-sale [Member] \| Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Number of facilities		9

Basis of Presentation - Narrative (Details) $ in Millions	6 Months Ended
Basis of Presentation - Narrative (Details) $ in Millions	Jun. 30, 2015 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Noncash contribution	$ 93

Relationship with DuPont and Related Entities - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 29, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Affiliated Entity [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party		$ 0	$ 116,000,000	$ 0	$ 238,000,000
Cost of Goods [Member] \| Affiliated Entity [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party			10,000,000		23,000,000
Selling, General and Administrative Expenses [Member] \| Affiliated Entity [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party			100,000,000		205,000,000
Research and Development Expense [Member] \| Affiliated Entity [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party			6,000,000		10,000,000
Titanium Technologies [Member] \| Operating Segments [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales			1,000,000		2,000,000
Fluoroproducts [Member] \| Operating Segments [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales			16,000,000		34,000,000
Chemical Solutions [Member] \| Operating Segments [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales			$ 11,000,000		$ 21,000,000
Arrangement to Purchase Services and Materials [Member] \| Affiliated Entity [Member]
Related Party Transaction [Line Items]
Amount of agreement with related party	$ 190,000,000
Arrangement to Purchase Services and Materials [Member] \| Minimum [Member] \| Affiliated Entity [Member]
Related Party Transaction [Line Items]
Remaining agreement term	12 months
Arrangement to Purchase Services and Materials [Member] \| Maximum [Member] \| Affiliated Entity [Member]
Related Party Transaction [Line Items]
Remaining agreement term	15 months
Other Accrued Liabilities [Member] \| Arrangement to Purchase Services and Materials [Member] \| Affiliated Entity [Member]
Related Party Transaction [Line Items]
Deferred liability		$ 131,000,000		$ 131,000,000

Employee Separation and Asset Related Charges, Net - Charges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Restructuring and Related Activities [Abstract]
Employee separation (credit) charges	$ (2)	$ 61	$ 2	$ 61
Decommissioning and other charges	11	0	25	0
Asset related charges - Impairment	58	0	58	0
Total	$ 67	$ 61	$ 85	$ 61

Employee Separation and Asset Related Charges, Net - Narrative (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($) position	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	$ 67	$ 61	$ 85	$ 61
2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	0	$ 61	4	61
Transformation Plan Global Restructuring Programs [Member]
Restructuring Cost and Reserve [Line Items]
Workforce reductions (more than 430 positions) \| position		430
Titanium Technologies [Member] \| Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost remaining	30		30
Titanium Technologies [Member] \| Operating Segments [Member] \| 2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	0	$ 23	2	23
Fluoroproducts [Member] \| Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost remaining	5		5
Fluoroproducts [Member] \| Operating Segments [Member] \| 2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	0	25	2	25
Plant and product line closures [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	9	0	23	0
Plant and product line closures [Member] \| Titanium Technologies [Member] \| Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	9	0	18	0
Plant and product line closures [Member] \| Fluoroproducts [Member] \| Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	$ 1	0	$ 5	$ 0
Employee Separation [Member] \| Transformation Plan Global Restructuring Programs [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net		$ 61

Employee Separation and Asset Related Charges, Net - Segment Earnings (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	$ 67	$ 61	$ 85	$ 61
2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	0	61	4	61
Corporate and Other [Member] \| 2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net		13		13
Operating Segments [Member] \| 2015 Restructuring Program [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	0	23	2	23
Operating Segments [Member] \| 2015 Restructuring Program [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	0	25	2	25
Operating Segments [Member] \| 2015 Restructuring Program [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	0	13	0	13
Plant and product line closures [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	9	0	23	0
Plant and product line closures [Member] \| Operating Segments [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	9	0	18	0
Plant and product line closures [Member] \| Operating Segments [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	1	0	5	0
Plant and product line closures [Member] \| Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	$ (1)	$ 0	$ 0	$ 0

Employee Separation and Asset Related Charges, Net - Restructuring Program Schedule (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance		$ 98
Restructuring charges		2
Payments		(41)
Net currency translation adjustment		0
Restructuring reserve, ending balance	$ 59	59
Titanium Technologies Site Closure [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance		11
Restructuring charges		0
Payments		(4)
Net currency translation adjustment		0
Restructuring reserve, ending balance	7	7
Fluoroproducts Lines Shutdown [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance		2
Restructuring charges		0
Payments		(1)
Net currency translation adjustment		0
Restructuring reserve, ending balance	1	1
Chemical Solutions Site Closures [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance		12
Restructuring charges	(2)	(2)
Payments		0
Net currency translation adjustment		0
Restructuring reserve, ending balance	10	10
2015 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance		73
Restructuring charges		4
Payments		(36)
Net currency translation adjustment		0
Restructuring reserve, ending balance	$ 41	41
Maximum [Member]
Restructuring Reserve [Roll Forward]
Net currency translation adjustment		$ 1

Sales of Assets and Businesses - Narrative (Details) - USD ($) $ in Millions			1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 29, 2016	Mar. 01, 2016	May 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 13, 2016	Apr. 22, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of assets							$ 88
Asset related charges				$ 63	$ 0		63	$ 0
Assets Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net book value of assets disposed				378			378				$ 46
Goodwill				13			13				$ 4
Aniline Facility, Beaumont, Texas [Member] \| Disposal group, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds from sale of facility		$ 140
Net book value of assets disposed		41
Transaction costs		$ 11
Clean and Disinfect Product Line [Member] \| Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price										$ 230
Net book value of assets disposed				39			39
Goodwill				13			13
Liabilities of assets held-for-sale				4			4
Sulfur Business [Member] \| Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price									$ 325
Net book value of assets disposed				339			339
Sulfur Business [Member] \| Assets Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds from sale of facility			$ 10
Asset related charges				$ 58			$ 58
Scenario, Forecast [Member] \| Clean and Disinfect Product Line [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of assets						$ 185
Subsequent Event [Member] \| Sulfur Business [Member] \| Assets Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds from sale of facility	$ 311

Sales of Assets and Businesses - Major Components of Assets Held-for-sale (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total current assets	$ 26	$ 46
Total non-current assets, net	352	0
Assets Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivables	21	0
Inventories	5	5
Total current assets	26	5
Property, plant and equipment, net	260	30
Goodwill	13	4
Other assets	137	7
Less: Impairment loss	(58)	0
Total non-current assets, net	352	41
Total assets held-for-sale, net	$ 378	$ 46

Other Income (Expense), Net - Schedule of Other Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Other Income and Expenses [Abstract]
Leasing, contract services and miscellaneous income	$ 5	$ 0	$ 12	$ 4
Royalty income	6	2	9	7
(Loss) gain on sale of assets or business	(1)	0	88	0
Exchange (losses) gains, net	(14)	19	(20)	3
Total other (expense) income, net	$ (4)	$ 21	$ 89	$ 14

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes	$ (23)	$ 0	$ (5)	$ 15
Effective income tax rate	56.00%	0.00%	(18.00%)	38.00%
Increases in tax expense (benefits)	$ (23)		$ (20)

Earnings Per Share of Common Stock - Earnings per Share Calculation (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
	Jul. 01, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Numerator:
Net income attributable to Chemours (in usd)		$ (18)	$ (18)	$ 33	$ 25
Denominator:
Weighted-average number of common shares outstanding- Basic		181,477,672	180,966,833	181,379,419	180,966,833
Dilutive effect of the company's employee compensation plans		0	0	668,410	0
Weighted average number of common shares outstanding - Diluted 2		181,477,672	180,966,833	182,047,829	180,966,833
Stock issued, common stock	180,966,833

Earnings Per Share of Common Stock - Antidilutive Shares Excluded from Computation of Earnings per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Earnings Per Share [Abstract]
Average number of stock options	7,356,050	0	8,028,762	0

Accounts and Notes Receivable - Trade, Net - Schedule of Accounts and Notes Receivable (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Receivables [Abstract]
Accounts receivable—trade, net	$ 849	$ 759
VAT, GST and other taxes	74	68
Leases receivable—current	0	13
Other receivables	16	19
Total	939	859
Allowance for doubtful accounts receivable	$ 4	$ 4

Accounts and Notes Receivable - Trade, Net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Receivables [Abstract]
Bad debt expense (less than $1 million)	$ 1	$ 1	$ 1	$ 1

Inventories (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Inventory, Net [Abstract]
Finished products	$ 628	$ 613
Semi-finished products	169	172
Raw materials, stores and supplies	332	433
Subtotal	1,129	1,218
Adjustment of inventories to a last-in, first-out (LIFO) basis	(237)	(246)
Total	892	972
LIFO inventory amount	$ 640	$ 744
Percentage of LIFO inventory	57.00%	61.00%

Property, Plant, and Equipment - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 73	$ 66	$ 138	$ 129
Capital leased assets	$ 7		$ 7		$ 7

Goodwill and Other Intangible Assets, Net - Schedule of Goodwill (Details) $ in Millions	6 Months Ended
	Jun. 30, 2016 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 166
Asset held-for-sale	(13)
Currency translation adjustment	0
Ending balance	153
Net currency translation adjustment (less than $1 million)	0
Operating Segments [Member] \| Titanium Technologies [Member]
Goodwill [Roll Forward]
Beginning balance	13
Asset held-for-sale	0
Currency translation adjustment	0
Ending balance	13
Operating Segments [Member] \| Fluroproducts [Member]
Goodwill [Roll Forward]
Beginning balance	85
Asset held-for-sale	0
Currency translation adjustment	0
Ending balance	85
Operating Segments [Member] \| Chemical Solutions [Member]
Goodwill [Roll Forward]
Beginning balance	68
Asset held-for-sale	(13)
Currency translation adjustment	0
Ending balance	55
Maximum [Member]
Goodwill [Roll Forward]
Net currency translation adjustment (less than $1 million)	$ 1

Goodwill and Other Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 39	$ 45
Finite-lived intangible assets, accumulated amortization	(31)	(35)
Finite-lived intangible assets, net	8	10
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	12	13
Finite-lived intangible assets, accumulated amortization	(10)	(10)
Finite-lived intangible assets, net	2	3
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	19	19
Finite-lived intangible assets, accumulated amortization	(17)	(17)
Finite-lived intangible assets, net	2	2
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	5	5
Finite-lived intangible assets, accumulated amortization	(2)	(2)
Finite-lived intangible assets, net	3	3
Purchased and Licensed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	3	8
Finite-lived intangible assets, accumulated amortization	(2)	(6)
Finite-lived intangible assets, net	$ 1	$ 2

Goodwill and Other Intangible Assets, Net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 1	$ 1	$ 1	$ 2
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life			5 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life			20 years

Goodwill and Other Intangible Assets, Net - Summary of Amortization Expense by Maturity (Details) $ in Millions	Jun. 30, 2016 USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2016	$ 1
2017	2
2018	1
2019	1
2020	$ 1

Other Assets (Details) $ in Millions	6 Months Ended
Other Assets (Details) $ in Millions	Jun. 30, 2016 USD ($) facility	Dec. 31, 2015 USD ($)
Other Assets [Abstract]
Leases receivable - non-current	$ 0	$ 125
Capitalized repair and maintenance costs	111	149
Pension assets	164	138
Deferred income taxes - non-current	46	47
Miscellaneous	48	49
Total	$ 369	508
Number of facilities with fixed assets constructed on land \| facility	2
Leases receivable	$ 131	138
Revolving Credit Facility [Member]
Other Assets [Abstract]
Deferred financing fee	$ 15	$ 19

Debt - Components of Long-Term Debt (Details) € in Millions, $ in Millions	Jun. 30, 2016 USD ($)	Jun. 30, 2016 EUR (€)	Dec. 31, 2015 USD ($)	Dec. 31, 2015 EUR (€)	Jul. 01, 2015 EUR (€)
Debt Instrument [Line Items]
Long-term debt	$ 3,914		$ 4,014
Less: Unamortized issue discount on senior secured term loan	6		7
Less: Unamortized debt issuance costs	49		53
Less: Current maturities	36		39
Total long-term debt	3,823		3,915
Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 1,308		$ 1,350
Debt instrument interest rate	6.625%	6.625%	6.625%	6.625%
Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 750		$ 750
Debt instrument interest rate	7.00%	7.00%	7.00%	7.00%
Senior Notes [Member] \| 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 398		$ 395
Debt instrument interest rate	6.125%	6.125%	6.125%	6.125%
Long-term debt, gross \| €		€ 360		€ 360	€ 360
Other [Member]
Debt Instrument [Line Items]
Long-term debt	$ 23		$ 26
The Term Loan Facility [Member]
Debt Instrument [Line Items]
Long-term debt	$ 1,435		$ 1,493
Debt instrument interest rate	1.00%	1.00%

Debt - Senior Secured Credit Facilities Narrative (Details)		3 Months Ended		6 Months Ended	12 Months Ended	18 Months Ended
	Jan. 01, 2019	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Jun. 30, 2017	Dec. 31, 2016	Jan. 01, 2019	Jun. 30, 2017	Dec. 31, 2015 USD ($)
Line of Credit Facility [Line Items]
Gain on extinguishment (less than $1 million for senior secured term loans)		$ 1,000,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			$ 750,000,000					$ 1,000,000,000
Write off of debt issuance costs (less than $1 million for senior secured term loans)			4,000,000
Other Assets [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Capitalized debt costs			$ 2,000,000
Scenario, Forecast [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Maximum net leverage ratio	2.00			3.00	3.50
Semi-annual decrease in maximum net leverage ratio						0.25
Minimum interest coverage ratio	3.00						1.75
Semi-annual increase in minimum interest coverage ratio						0.25
Senior Secured Term Loans [Member]
Line of Credit Facility [Line Items]
Write off of debt issuance costs (less than $1 million for senior secured term loans)		1,000,000
Face amount repurchased		50,000,000
Amount repurchased		$ 49,000,000

Debt - Senior Unsecured Notes Narrative (Details)	3 Months Ended
Debt - Senior Unsecured Notes Narrative (Details)	Jun. 30, 2016 USD ($)	May 12, 2015 USD ($)	May 12, 2015 EUR (€)
Debt Instrument [Line Items]
Gain on extinguishment (less than $1 million for senior secured term loans)	$ 1,000,000
Notes Payable [Member]
Debt Instrument [Line Items]
Face amount repurchased	42,000,000
Amount repurchased	36,000,000
Gain on extinguishment (less than $1 million for senior secured term loans)	5,000,000
Write off of debt issuance costs (less than $1 million for senior secured term loans)	$ 1,000,000
2023 Notes [Member]
Debt Instrument [Line Items]
Face amount		$ 1,350,000,000
2025 Notes [Member]
Debt Instrument [Line Items]
Face amount		$ 750,000,000
Euro Notes [Member]
Debt Instrument [Line Items]
Face amount \| €			€ 360,000,000

Debt - Maturities and Fair Value Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.625%	6.625%
Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	7.00%	7.00%
Senior Notes [Member] \| 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%
Level 2 [Member] \| Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 1,105
Level 2 [Member] \| Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Notes, fair value	628
Level 2 [Member] \| Senior Notes [Member] \| 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 312
The Term Loan Facility [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	1.00%
2016	$ 8
2017	15
2018	15
2019	15
2020	15
2021	15
2022 and beyond	$ 3,808
Covenant terms, additional principal prepayment. percentage of excess cash flow	50.00%
Covenant terms, additional principal prepayment. percentage of excess cash flow, stepdown level 1	25.00%
Covenant terms, additional principal prepayment. percentage of excess cash flow, stepdown level 2	0.00%
The Term Loan Facility [Member] \| Level 2 [Member]
Debt Instrument [Line Items]
Line of credit facility, fair value	$ 1,392

Commitments and Contingent Liabilities - Guarantees Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Guarantee obligations	$ 8	$ 8

Commitments and Contingent Liabilities - Litigation Narrative (Details) resident in Thousands		1 Months Ended			3 Months Ended		6 Months Ended	12 Months Ended
	Oct. 20, 2015 USD ($)	Oct. 31, 2015 USD ($)	Sep. 30, 2014	May 31, 2013 doctor	Jun. 30, 2016 USD ($) lawsuit claim	Sep. 30, 2014 plantiff	Jun. 30, 2016 USD ($) lawsuit water_district claim plantiff	Dec. 31, 2015 USD ($) lawsuit	Dec. 31, 2005 USD ($)	Dec. 31, 2004 resident	Jan. 31, 2012 USD ($)
Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Escrow deposit disbursements (less than $1)							$ 1,000,000
Asbestos Issue [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit					1,979		1,979	2,212
Accrual balance					$ 44,000,000		$ 44,000,000	$ 44,000,000
Annual review projection period							20 years
Benzene Related Illness [Member]
Loss Contingencies [Line Items]
Lawsuits alleging illness \| lawsuit					28		28	29
Years of exposure to benzene	24 years
Compensatory damages awarded	$ 6,900,000
Punitive damages awarded	$ 1,500,000
PFOA Matters [Member]
Loss Contingencies [Line Items]
Accrual balance					$ 19,000,000		$ 19,000,000	$ 20,000,000
Additional accrual related to lawsuit					$ 4,000,000
PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Binding settlement agreement, class size \| resident										80
Number of doctors to release initial screening recommendations \| doctor				3
Medical panel follow-up screening and diagnostic testing period			3 years
Number of water districts Company must provide treatment \| water_district							6
Expected number of scheduled plaintiff trials annually \| plantiff							40
Percentage of cases to remain active							93.00%
PFOA Matters: Drinking Water Actions [Member] \| Payment for Plaintiffs Attorney Fees [Member]
Loss Contingencies [Line Items]
Settlement payments									$ 23,000,000
PFOA Matters: Drinking Water Actions [Member] \| Payment to fund community health project [Member]
Loss Contingencies [Line Items]
Settlement payments									$ 70,000,000
PFOA Matters: Drinking Water Actions [Member] \| Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Escrow deposit											$ 1,000,000
PFOA Matters: Drinking Water Actions - Cancer Cases [Member]
Loss Contingencies [Line Items]
Lawsuits alleging illness \| claim					270		270
PFOA Matters: Additional Actions [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit					3,500		3,500
Increase in claims \| lawsuit								600
Lawsuits alleging wrongful death \| lawsuit					30		30
Maximum [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss					$ 600,000,000		$ 600,000,000
Maximum [Member] \| PFOA Matters: Drinking Water Actions [Member] \| Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss					$ 235,000,000		$ 235,000,000
Bellwether Case [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded		$ 5,100,000
Punitive damages awarded		500,000
Bellwether Case [Member] \| PFOA Matters: Additional Actions [Member]
Loss Contingencies [Line Items]
Number of plaintiffs \| plantiff						6
Damages awarded due to negligence		1,100,000
Damages awarded due to emotional distress		$ 500,000
Bellwether Case [Member] \| PFOA Matters: Additional Actions [Member] \| Litigation Tried [Member]
Loss Contingencies [Line Items]
Number of plaintiffs \| plantiff							2
Bellwether Case [Member] \| PFOA Matters: Additional Actions [Member] \| Settled Litigation [Member]
Loss Contingencies [Line Items]
Number of plaintiffs \| plantiff							3

Commitments and Contingent Liabilities - Summary of Alleged Injuries in Lawsuit (Details)	6 Months Ended
	Jun. 30, 2016 plantiff
PFOA Matters - Kidney Cancer [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	200
PFOA Matters - Testicular Cancer [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	70
PFOA Matters - Ulcerative Colitis [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	300
PFOA Matters - Preeclampsia [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	200
PFOA Matters - Thyroid Disease [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	1,430
PFOA Matters - High Cholestrol [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	1,340

Commitments and Contingent Liabilities - Environmental Narrative (Details)	6 Months Ended
	Jun. 30, 2016 USD ($)	Dec. 31, 2015 USD ($)	Jun. 30, 2015 a
Environmental Remediation [Line Items]
Accrual for environmental remediation activities	$ 290,000,000	$ 290,000,000
Pompton Lakes [Member] \| Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Accrual for environmental remediation activities	86,000,000	$ 87,000,000
Area of lake \| a			36
Environmental remediation expense	$ 50,000,000
Minimum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	15 years
Minimum [Member] \| Pompton Lakes [Member] \| Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	2 years
Maximum [Member]
Environmental Remediation [Line Items]
Loss contingency, potential additional loss	$ 600,000,000
Average time frame of disbursements of environmental site remediation	20 years
Maximum [Member] \| Pompton Lakes [Member] \| Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Loss contingency, potential additional loss	$ 119,000,000
Average time frame of disbursements of environmental site remediation	3 years

Financial Instruments - Narrative (Details) € in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016 USD ($) contract	Jun. 30, 2015 USD ($)	Jun. 30, 2016 USD ($) contract	Jun. 30, 2015 USD ($)	Jun. 30, 2016 EUR (€) contract	Dec. 31, 2015 EUR (€)	Jul. 01, 2015 EUR (€)
Derivative [Line Items]
Recognized gain (loss) on derivative net investment hedge	$ 4		$ (3)
6.125% Due May 2023 [Member] \| Senior Notes [Member]
Derivative [Line Items]
Long-term debt, gross \| €					€ 360	€ 360	€ 360
Foreign Exchange Contract [Member]
Derivative [Line Items]
Number of forward exchange currency contracts \| contract	47		47		47
Derivative notional value	$ 270		$ 270
Foreign Exchange Contract [Member] \| Not Designated as Hedging Instrument [Member] \| Other Income [Member]
Derivative [Line Items]
Derivative gain (loss)	$ 1	$ 23	$ (1)	$ 12

Financial Instruments - Schedule of the Fair Value of Derivative Instruments (Details) - Recurring [Member] - Level 2 [Member] - Not Designated as Hedging Instrument [Member] - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Derivatives, Fair Value [Line Items]
Asset derivatives	$ 2	$ 2
Liability derivatives	2	2
Foreign Exchange Contract [Member] \| Accounts and notes receivable - trade, net [Member]
Derivatives, Fair Value [Line Items]
Asset derivatives	2	2
Foreign Exchange Contract [Member] \| Other accrued liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability derivatives	$ 2	$ 2

Long-Term Employee Benefits - Schedules of Net Periodic Benefit Cost (Details) - Foreign Pension Plan [Member] - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 4	$ 3	$ 7	$ 6
Interest cost	5	4	10	9
Expected return on plan assets	(17)	(20)	(33)	(41)
Amortization of actuarial net loss	7	3	11	7
Amortization of prior service cost (gain)	0	1	(1)	2
Curtailment gain	(2)	0	(2)	0
Net periodic benefit income	$ (3)	$ (9)	$ (8)	$ (17)

Long-Term Employee Benefits - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
Pension and other long-term benefit expense		$ 26		$ 53
Foreign Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer	$ 5		$ 9
Estimated future employer contributions in current fiscal year			$ 9

Stock-based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended		6 Months Ended
	Jul. 01, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost (less than $1 million for performance shares)		$ 5	$ 3	$ 10	$ 5
Income tax benefit		2	$ 1	$ 4	$ 2
Options granted during period (shares)			0		0
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award vesting period				3 years
Expiration period				10 years
Options granted during period (shares)				1,406,000
Unrecognized compensation cost related to stock options		$ 6		$ 6
Unrecognized compensation cost period for recognition				1 year 9 months 10 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award vesting period				3 years
Unrecognized compensation cost period for recognition				1 year 11 months 5 days
Shares issued upon conversion of equity award		1		1
Unrecognized compensation cost related to equity awards other than options		$ 21		$ 21
Weighted-average fair value at grant date (in dollars per share)				$ 6.04
Performance Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost (less than $1 million for performance shares)		$ 1		$ 1
Stock-based compensation award vesting period				3 years
Shares issued upon conversion of equity award		1		1
Weighted-average fair value at grant date (in dollars per share)		$ 6.10		$ 6.10
Minimum [Member] \| Performance Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target award available for grant				0.00%
Maximum [Member] \| Performance Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target award available for grant				200.00%
Chemours Company Equity and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for grants (in shares)	13,500,000	8,594,630		8,594,630
Requisite service period	6 months

Stock-based Compensation - Stock Option Assumptions (Details) - Stock Option [Member]	6 Months Ended
	Jun. 30, 2016 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.46%
Expected term (years)	6 years
Volatility	80.90%
Dividend yield	2.14%
Fair value per stock option (in dollars per share)	$ 3.41

Stock-based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Granted, shares	0		0
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning balance, shares		8,284,000
Granted, shares		1,406,000
Exercised, shares		(12,000)
Forfeited, shares		(252,000)
Expired, shares		(356,000)
Outstanding, ending balance, shares		9,070,000		8,284,000
Exercisable, shares		4,928,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding, weighted average exercise price, beginning balance (in dollars per share)		$ 14.66
Granted, weighted average exercise price (in dollars per share)		5.73
Exercised, weighted average exercise price (in dollars per share)		8.38
Forfeited, weighted average exercise price (in dollars per share)		15.46
Expired, weighted average exercise price (in dollars per share)		5.82
Outstanding, weighted average exercise price, ending balance (in dollars per share)		13.60		$ 14.66
Exercisable, weighted average exercise price (in dollars per share)		$ 13.69
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options outstanding, weighted average remaining contractual term		5 years 3 months 12 days		4 years 9 months 26 days
Options exercisable, weighted average remaining contractual term		3 years 6 months 20 days
Options outstanding, aggregate intrinsic value		$ 3,556		$ 0
Options exercisable, aggregate intrinsic value		$ 0

Stock-based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	6 Months Ended
	Jun. 30, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning balance, shares \| shares	2,349
Granted, shares \| shares	948
Vested, shares \| shares	(554)
Forfeited, shares \| shares	(167)
Nonvested, ending balance, shares \| shares	2,576
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested, weighted average grant date fair value, beginning balance (in dollars per share) \| $ / shares	$ 14.87
Granted, weighted average grant date fair value (in dollars per share) \| $ / shares	6.04
Vested, weighted average grant date fair value (in dollars per share) \| $ / shares	15.98
Forfeited, weighted average grant date fair value (in dollars per share) \| $ / shares	15.82
Nonvested, weighted average grant date fair value, ending balance (in dollars per share) \| $ / shares	$ 11.40

Stock-based Compensation - Performance Share Units Activity (Details) - Performance Share Units [Member] - $ / shares shares in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning balance, shares		0
Granted, shares		825
Vested, shares		0
Forfeited, shares		(22)
Nonvested, ending balance, shares	803	803
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested, weighted average grant date fair value, beginning balance (in dollars per share)		$ 0.00
Granted, weighted average grant date fair value (in dollars per share)	$ 6.10	6.10
Vested, weighted average grant date fair value (in dollars per share)		0.00
Forfeited, weighted average grant date fair value (in dollars per share)		6.10
Nonvested, weighted average grant date fair value, ending balance (in dollars per share)	$ 6.10	$ 6.10

Segment Information - Narrative (Details)	6 Months Ended
Segment Information - Narrative (Details)	Jun. 30, 2016 segment
Segment Reporting [Abstract]
Number of reportable segments	3

Segment Information - Schedule of Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Net sales	$ 1,383	$ 1,508	$ 2,680	$ 2,871
Adjusted EBITDA	187	127	315	272
Depreciation and amortization	73	67	139	131
Corporate and Other [Member]
Net sales	0	0	0	0
Adjusted EBITDA	(40)	(22)	(62)	(46)
Depreciation and amortization	8	0	16	0
Titanium Technologies [Member] \| Operating Segments [Member]
Net sales	596	642	1,117	1,187
Adjusted EBITDA	111	91	166	184
Depreciation and amortization	32	32	54	63
Fluoroproducts [Member] \| Operating Segments [Member]
Net sales	573	588	1,104	1,140
Adjusted EBITDA	105	54	190	129
Depreciation and amortization	25	21	49	42
Chemical Solutions [Member] \| Operating Segments [Member]
Net sales	214	278	459	544
Adjusted EBITDA	11	4	21	5
Depreciation and amortization	$ 8	$ 14	$ 20	$ 26

Segment Information - Reconciliation to Consolidated Income Statements (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Segment Reporting Information [Line Items]
(Loss) income before income taxes	$ (41)	$ (18)	$ 28	$ 40
Interest expense, net	50	28	106	28
Depreciation and amortization	73	67	139	131
Non-operating pension and other postretirement employee benefit (income) costs	(7)	8	(14)	15
Exchange losses (gains)	14	(19)	20	(3)
Restructuring charges	9	61	27	61
Asset related charges	63	0	63	0
Gain on sale of assets and business	1	0	(88)	0
Transaction costs	12	0	15	0
Legal and other charges	13	0	19	0
Adjusted EBITDA	187	$ 127	315	$ 272
Sulfur Business [Member] \| Assets Held-for-sale [Member]
Segment Reporting Information [Line Items]
Asset related charges	$ 58		$ 58

Guarantor Condensed Consolidating Financial Information - Statements of Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Condensed Statement of Income Captions [Line Items]
Net sales	$ 1,383	$ 1,508	$ 2,680	$ 2,871
Cost of goods sold	1,116	1,282	2,212	2,393
Gross profit	267	226	468	478
Selling, general and administrative expense	174	157	307	324
Research and development expense	17	27	40	50
Employee separation and asset related charges, net	67	61	85	61
Total expenses	258	245	432	435
Equity in earnings of affiliates	4	8	9	11
Equity in earnings of subsidiaries	0	0	0	0
Interest expense, net	(50)	(28)	(106)	(28)
Intercompany interest income (expense), net	0	0	0	0
Other (expense) income, net	(4)	21	89	14
(Loss) income before income taxes	(41)	(18)	28	40
(Benefit from) provision for income taxes	(23)	0	(5)	15
Net (loss) income	(18)	(18)	33	25
Less: Net income attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Chemours	(18)	(18)	33	25
Comprehensive (loss) income attributable to Chemours	(22)	(49)	40	(182)
Parent Company [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expense	5	0	12	0
Research and development expense	0	0	0	0
Employee separation and asset related charges, net	0	0	0	0
Total expenses	5	0	12	0
Equity in earnings of affiliates	0	0	0	0
Equity in earnings of subsidiaries	5	(8)	81	35
Interest expense, net	(50)	(28)	(105)	(28)
Intercompany interest income (expense), net	14	12	29	12
Other (expense) income, net	5	0	10	0
(Loss) income before income taxes	(31)	(24)	3	19
(Benefit from) provision for income taxes	(13)	(6)	(30)	(6)
Net (loss) income	(18)	(18)	33	25
Less: Net income attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Chemours	(18)	(18)	33	25
Comprehensive (loss) income attributable to Chemours	$ (22)	(49)	$ 40	(182)
Guarantor Subsidiaries [Member]
Condensed Statement of Income Captions [Line Items]
Ownership percentage	100.00%		100.00%
Net sales	$ 956	1,087	$ 1,937	2,114
Cost of goods sold	840	1,001	1,715	1,893
Gross profit	116	86	222	221
Selling, general and administrative expense	138	100	236	209
Research and development expense	16	25	38	48
Employee separation and asset related charges, net	69	39	87	39
Total expenses	223	164	361	296
Equity in earnings of affiliates	(3)	0	(3)	0
Equity in earnings of subsidiaries	0	0	0	0
Interest expense, net	0	0	(1)	0
Intercompany interest income (expense), net	2	0	3	0
Other (expense) income, net	9	20	108	18
(Loss) income before income taxes	(99)	(58)	(32)	(57)
(Benefit from) provision for income taxes	(33)	8	(4)	8
Net (loss) income	(66)	(66)	(28)	(65)
Less: Net income attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Chemours	(66)	(66)	(28)	(65)
Comprehensive (loss) income attributable to Chemours	(66)	(66)	(28)	(65)
Non-Guarantor Subsidiaries [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	799	871	1,520	1,632
Cost of goods sold	648	729	1,266	1,382
Gross profit	151	142	254	250
Selling, general and administrative expense	36	57	69	115
Research and development expense	1	2	2	2
Employee separation and asset related charges, net	(2)	22	(2)	22
Total expenses	35	81	69	139
Equity in earnings of affiliates	7	8	12	11
Equity in earnings of subsidiaries	0	0	0	0
Interest expense, net	0	0	0	0
Intercompany interest income (expense), net	(16)	(12)	(32)	(12)
Other (expense) income, net	(17)	1	(22)	(4)
(Loss) income before income taxes	90	58	143	106
(Benefit from) provision for income taxes	15	(2)	24	13
Net (loss) income	75	60	119	93
Less: Net income attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Chemours	75	60	119	93
Comprehensive (loss) income attributable to Chemours	67	29	129	(114)
Eliminations and Adjustments [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	(372)	(450)	(777)	(875)
Cost of goods sold	(372)	(448)	(769)	(882)
Gross profit	0	(2)	(8)	7
Selling, general and administrative expense	(5)	0	(10)	0
Research and development expense	0	0	0	0
Employee separation and asset related charges, net	0	0	0	0
Total expenses	(5)	0	(10)	0
Equity in earnings of affiliates	0	0	0	0
Equity in earnings of subsidiaries	(5)	8	(81)	(35)
Interest expense, net	0	0	0	0
Intercompany interest income (expense), net	0	0	0	0
Other (expense) income, net	(1)	0	(7)	0
(Loss) income before income taxes	(1)	6	(86)	(28)
(Benefit from) provision for income taxes	8	0	5	0
Net (loss) income	(9)	6	(91)	(28)
Less: Net income attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Chemours	(9)	6	(91)	(28)
Comprehensive (loss) income attributable to Chemours	$ (1)	$ 37	$ (101)	$ 179

Guarantor Condensed Consolidating Financial Information - Balance Sheets (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 383	$ 366
Accounts and notes receivable - trade, net	939	859
Intercompany receivable	0	0
Inventories	892	972
Prepaid expenses and other	52	58
Assets held-for-sale	26	46
Total current assets	2,292	2,301
Property, plant and equipment	8,334	9,015
Less: Accumulated depreciation	(5,444)	(5,838)
Net property, plant and equipment	2,890	3,177
Goodwill	153	166
Other intangible assets, net	8	10
Investments in affiliates	157	136
Investment in subsidiaries	0	0
Intercompany notes receivable	0	0
Assets held-for-sale	352	0
Other assets	369	508
Total assets	6,221	6,298
Current liabilities:
Accounts payable	875	973
Short-term borrowings and current maturities of long-term debt	36	39
Intercompany payable	0	0
Other accrued liabilities	533	454
Total current liabilities	1,444	1,466
Long-term debt	3,823	3,915
Intercompany notes payable	0	0
Deferred income taxes	202	234
Other liabilities	583	553
Total liabilities	6,052	6,168
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	165	126
Noncontrolling interests	4	4
Total equity	169	130	$ 405	$ 3,673
Total liabilities and equity	6,221	6,298
Eliminations and Adjustments [Member]
Current assets:
Cash	0	0
Accounts and notes receivable - trade, net	0	0
Intercompany receivable	(743)	(516)
Inventories	(28)	(22)
Prepaid expenses and other	(15)	3
Assets held-for-sale	0	0
Total current assets	(786)	(535)
Property, plant and equipment	0	0
Less: Accumulated depreciation	0	0
Net property, plant and equipment	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Investments in affiliates	0	0
Investment in subsidiaries	(3,250)	(3,105)
Intercompany notes receivable	(1,150)	(1,150)
Assets held-for-sale	0
Other assets	0	0
Total assets	(5,186)	(4,790)
Current liabilities:
Accounts payable	0	0
Short-term borrowings and current maturities of long-term debt	0	0
Intercompany payable	(743)	(516)
Other accrued liabilities	0	0
Total current liabilities	(743)	(516)
Long-term debt	0	0
Intercompany notes payable	(1,150)	(1,150)
Deferred income taxes	17	0
Other liabilities	0	0
Total liabilities	(1,876)	(1,666)
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	(3,310)	(3,124)
Noncontrolling interests	0	0
Total equity	(3,310)	(3,124)
Total liabilities and equity	(5,186)	(4,790)
Parent Company [Member]
Current assets:
Cash	0	0
Accounts and notes receivable - trade, net	0	0
Intercompany receivable	2	3
Inventories	0	0
Prepaid expenses and other	0	0
Assets held-for-sale	0	0
Total current assets	2	3
Property, plant and equipment	0	0
Less: Accumulated depreciation	0	0
Net property, plant and equipment	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Investments in affiliates	0	0
Investment in subsidiaries	3,250	3,105
Intercompany notes receivable	1,150	1,150
Assets held-for-sale	0
Other assets	15	19
Total assets	4,417	4,277
Current liabilities:
Accounts payable	0	0
Short-term borrowings and current maturities of long-term debt	15	15
Intercompany payable	393	202
Other accrued liabilities	23	21
Total current liabilities	431	238
Long-term debt	3,821	3,913
Intercompany notes payable	0	0
Deferred income taxes	0	0
Other liabilities	0	0
Total liabilities	4,252	4,151
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	165	126
Noncontrolling interests	0	0
Total equity	165	126
Total liabilities and equity	4,417	4,277
Guarantor Subsidiaries [Member]
Current assets:
Cash	71	95
Accounts and notes receivable - trade, net	422	344
Intercompany receivable	677	459
Inventories	413	493
Prepaid expenses and other	17	3
Assets held-for-sale	20	46
Total current assets	1,620	1,440
Property, plant and equipment	6,394	7,070
Less: Accumulated depreciation	(4,491)	(4,899)
Net property, plant and equipment	1,903	2,171
Goodwill	139	141
Other intangible assets, net	8	10
Investments in affiliates	6	9
Investment in subsidiaries	0	0
Intercompany notes receivable	0	0
Assets held-for-sale	339
Other assets	119	275
Total assets	4,134	4,046
Current liabilities:
Accounts payable	575	637
Short-term borrowings and current maturities of long-term debt	21	24
Intercompany payable	64	54
Other accrued liabilities	395	287
Total current liabilities	1,055	1,002
Long-term debt	2	2
Intercompany notes payable	0	0
Deferred income taxes	134	173
Other liabilities	479	456
Total liabilities	1,670	1,633
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	2,464	2,413
Noncontrolling interests	0	0
Total equity	2,464	2,413
Total liabilities and equity	4,134	4,046
Non-Guarantor Subsidiaries [Member]
Current assets:
Cash	312	271
Accounts and notes receivable - trade, net	517	515
Intercompany receivable	64	54
Inventories	507	501
Prepaid expenses and other	50	52
Assets held-for-sale	6	0
Total current assets	1,456	1,393
Property, plant and equipment	1,940	1,945
Less: Accumulated depreciation	(953)	(939)
Net property, plant and equipment	987	1,006
Goodwill	14	25
Other intangible assets, net	0	0
Investments in affiliates	151	127
Investment in subsidiaries	0	0
Intercompany notes receivable	0	0
Assets held-for-sale	13
Other assets	235	214
Total assets	2,856	2,765
Current liabilities:
Accounts payable	300	336
Short-term borrowings and current maturities of long-term debt	0	0
Intercompany payable	286	260
Other accrued liabilities	115	146
Total current liabilities	701	742
Long-term debt	0	0
Intercompany notes payable	1,150	1,150
Deferred income taxes	51	61
Other liabilities	104	97
Total liabilities	2,006	2,050
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	846	711
Noncontrolling interests	4	4
Total equity	850	715
Total liabilities and equity	$ 2,856	$ 2,765

Guarantor Condensed Consolidating Financial Information - Statements of Cash Flows (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating activities
Cash (used for) provided by operating activities	$ 126	$ (233)
Investing activities
Purchases of property, plant and equipment	(168)	(287)
Proceeds from sales of assets and business	150	8
Foreign exchange contract settlements	0	(12)
Investment in affiliates	0	(32)
Intercompany investing activities	0
Cash used for investing activities	(18)	(323)
Financing activities
Proceeds from issuance of debt, net	0	3,490
Intercompany short-term borrowings, net	0
Debt repayments	(95)	0
Dividends paid	(11)	0
Deferred financing fees	(2)	(77)
Cash provided at separation by DuPont	0	247
Net transfers (to) from DuPont	0	(2,857)
Cash (used for) provided by financing activities	(108)	803
Effect of exchange rate changes on cash	17	0
Increase in cash	17	247
Cash at beginning of period	366	0
Cash at end of period	383	247
Eliminations and Adjustments [Member]
Operating activities
Cash (used for) provided by operating activities	163	(199)
Investing activities
Purchases of property, plant and equipment	0	0
Proceeds from sales of assets and business	0	0
Foreign exchange contract settlements		0
Investment in affiliates		0
Intercompany investing activities	28
Cash used for investing activities	28	0
Financing activities
Proceeds from issuance of debt, net		0
Intercompany short-term borrowings, net	(191)
Debt repayments	0
Dividends paid	0
Deferred financing fees	0	0
Cash provided at separation by DuPont		0
Net transfers (to) from DuPont		199
Cash (used for) provided by financing activities	(191)	199
Effect of exchange rate changes on cash	0	0
Increase in cash	0	0
Cash at beginning of period	0	0
Cash at end of period	0	0
Parent Company [Member]
Operating activities
Cash (used for) provided by operating activities	(86)	5
Investing activities
Purchases of property, plant and equipment	0	0
Proceeds from sales of assets and business	0	0
Foreign exchange contract settlements		0
Investment in affiliates		0
Intercompany investing activities	0
Cash used for investing activities	0	0
Financing activities
Proceeds from issuance of debt, net		3,489
Intercompany short-term borrowings, net	191
Debt repayments	(92)
Dividends paid	(11)
Deferred financing fees	(2)	(77)
Cash provided at separation by DuPont		0
Net transfers (to) from DuPont		(3,417)
Cash (used for) provided by financing activities	86	(5)
Effect of exchange rate changes on cash	0	0
Increase in cash	0	0
Cash at beginning of period	0	0
Cash at end of period	0	0
Guarantor Subsidiaries [Member]
Operating activities
Cash (used for) provided by operating activities	(48)	206
Investing activities
Purchases of property, plant and equipment	(95)	(173)
Proceeds from sales of assets and business	150	6
Foreign exchange contract settlements		(12)
Investment in affiliates		0
Intercompany investing activities	(28)
Cash used for investing activities	27	(179)
Financing activities
Proceeds from issuance of debt, net		1
Intercompany short-term borrowings, net	0
Debt repayments	(3)
Dividends paid	0
Deferred financing fees	0	0
Cash provided at separation by DuPont		87
Net transfers (to) from DuPont		(28)
Cash (used for) provided by financing activities	(3)	60
Effect of exchange rate changes on cash	0	0
Increase in cash	(24)	87
Cash at beginning of period	95	0
Cash at end of period	71	87
Non-Guarantor Subsidiaries [Member]
Operating activities
Cash (used for) provided by operating activities	97	(245)
Investing activities
Purchases of property, plant and equipment	(73)	(114)
Proceeds from sales of assets and business	0	2
Foreign exchange contract settlements		0
Investment in affiliates		(32)
Intercompany investing activities	0
Cash used for investing activities	(73)	(144)
Financing activities
Proceeds from issuance of debt, net		0
Intercompany short-term borrowings, net	0
Debt repayments	0
Dividends paid	0
Deferred financing fees	0	0
Cash provided at separation by DuPont		160
Net transfers (to) from DuPont		389
Cash (used for) provided by financing activities	0	549
Effect of exchange rate changes on cash	17	0
Increase in cash	41	160
Cash at beginning of period	271	0
Cash at end of period	$ 312	$ 160